Oner Ozdemir, MD was born in Alaplı, Zonguldak, Türkiye in September 18, 1965. He have graduated from İstanbul University İstanbul Medical School and become a medical doctor in 1989. He did pediatric residency at department of pediatrics in children’s hospital of İstanbul Medical School, İstanbul, Türkiye. His clinical fellowship training was finished at Pediat...
Oner Ozdemir, MD was born in Alaplı, Zonguldak, Türkiye in September 18, 1965. He have graduated from İstanbul University İstanbul Medical School and become a medical doctor in 1989. He did pediatric residency at department of pediatrics in children’s hospital of İstanbul Medical School, İstanbul, Türkiye. His clinical fellowship training was finished at Pediatric Allergy/Immunology division in Louisiana State University Health Sciences Ctr., New Orleans, LA. Some part of his clinical fellowship training was done at Pediatric Allergy/Immunology program in Cincinnati Children's Hospital Medical Center, Cincinnati, OH. Currently, He work as a chief and full professor of pediatrics and division of Allergy and Immunology at Sakarya University, Teaching and Training Hospital, Adapazarı, Sakarya, Türkiye. He was the first place winner of Clemens Von Pirquet Award from ACAAI at ACAAI meeting in 2005 for the best research on allergy/asthma/immunology by a fellow in training. He have more than 55 international plus 25 national publications, as well as 90 international and 40 national presentations. He have also more than 5 chapters related to my research areas.
LAK-cell generation and cell-mediated cytotoxicity; human mast cell development and mast cell-mediated cytotoxicity; and apoptosis -related research.
American Medical Diagnostic Laboratory Director USA
Dr. Nemat Khansari D.V.M., Ph.D. an Iranian native, he was awarded his D.V.M. degree from Tehran University, School of veterinary medicine (1970), Tehran, Iran. After six years practice in Tehran, in 1975, he immigrated to US. He earned his M.S. degree and followed by earning his Ph.D. in Immunology from University of Illinois (1981), Urbana, IL. He was then offered a post-doctoral position in the Department of microbiology and immunology, Medical Sciences University of South Carolina, Charleston, SD where he published 17 articles in well-respected journals like Sciences magazine. In 1983, he became Cellular Division Director in IMREG, Inc. in New Orleans, LU. In this position he was directing research on Imreg I and ImregII, which were purified endogenous immunomodulators to be applied for treatment and/or management of HIV infection. From 1985 to 1995, he served as assistant professor in the Department of Veterinary medical Science, North Dakota State University, Fargo, ND. In this position, in addition to teaching immunology, he was directing research in the field of aging immunology and re-juvenescence of aged mice using growth hormone and other immunomodulator. In 1990, he moved back to Tehran and accepted Deputy Director position in Iranian Pasteur Institute where he established Biotechnology division. He also served as Research Deputy Managing Director of Iranian Blood Bank. From 1991 to 2009, he served as Professor and Vice Chairman of the Department of Immunology, Tehran Medical School. After retirement from Medical School, he returned to US and since then he has been Director of NK-Immunotherapy Laboratory in Orange County, CA. He has published 51 research articles in English journals, 20 articles in Iranian journals and 12 books (in Biotechnology and immunology) in Farsi.
Identification and development of specific tumor marker for cancer diagnosis, Effect of inflammatory reactions in tumor growth and metastasis; Effect of anti-oxidant on prevention of tumor growth; Immunotherapy and cancer prevention measures
Soumita Das an Assistant Project Scientist in the department of Pathology at the University of California San Diego (UCSD). She have been working on the immunopathogenesis of gastroenteric bacteria for more than 12 years. She has expertise in biochemistry, immunology, molecular biology, bacterial pathogenesis and host cellular responses. Her research experience include identification of Vibrio cholerae transcripts following infection, gastric epithelial cell responses and the crosstalk between luminal antigen and T cells during Helicobacter pylori infection.
The attachment/internalization of enteric bacteria, the molecular basis of bacterial engulfment by phagocyte receptors and its effect on intestinal inflammation.
Armand Bensussan completed his PhD training during the early 1980sin the laboratories of Professor Jean Dausset (Saint-Louis Hospital, Paris, France) and Professor Stuart F Schlossman (Harvard Medical School, DFCI, Boston, MA). He is currently Research director at INSERM and chief of the Skin Research Center and of the INSERM unit 976 at Saint-Louis Hospital in Paris, France. He is also the director of the research at the cancer Institute Jean Godinot in Reims, France. He obtained several awards including two distinct French Academy of Sciences awards, the clinical investigation award from the French foundation for medical research, the immunology Bernard Halpern award and the national award of projects leaders for the creation and/or the development of highly innovative technology companies.He was the past president of the French society of immunology. He is the co-founder of the biotechnology companies Orega Biotech (www.orega-biotech.com) and Genepredict (www.genepredict.fr) His main scientific contributions have been in the field of basic and clinical immunology and in tumor dermatology. He discovered new targets for monoclonal antibody in cancer therapy, such as KIR3DL2 in Sézary syndrome (Bagot et al, Blood 2001; Marie-Cardine et al Cancer Res, 2014). He is author of more than 300 international scientific publications (H-index of 55, Google Scholar source), editor of two scientific books and co-inventor of 20 patents. He is an editorial board member of different international scientific journals and a member of the Human Cell Differentiation Molecules council(http://www.hcdm.org) and of the EuroMAbNet council (http://www.euromabnet.com).
Tumor Immunology, NK lymphocyte Biology, Immuno-dermatology, Cutaneous T cell lymphoma, T lymphocyte subsets (nTregs, Th17, Th22)
Roberto Bei, MD, PhD. is Associate Professor of General Pathology at the University of Rome “Tor Vergata” (Italy). He got his Degree in Medicine and his PhD at the University of Rome "Sapienza" in 1989 and 1998, respectively. He is specialist in Medical Oncology and in Clinical Pathology. He joined, as post-doctoral fellow (1992-1996), the LTIB at NIH (Director: Dr J. Schlom) where he started to work in the field of cancer immunotherapy. The teaching activity of Prof. Bei includes lectures of General Pathology in the School of Medicine, Human Nutrition, Medicine Biotechnology, Pharmacy, Dietician, Radiology Technician, Residency in Endocrinology and Oncology. He is a Member of the Editorial Board of The Open Pathology Journal (2009-2012), Recent Pat Inflamm Allergy Drug Discov, Journal of Chinese Clinical Medicine, J Liver, Open J Immunology, Open J Pathology, Dataset Papers in Biology, Journal of Life Medicine, Pathology Discovery, Frontiers in Pathogenic Biology, American Journal of Current Immunology (Advisory), Frontiers in Pharmaceutical Sciences, World Research Journal of Translational Medicine (Associate Editor). He serves as ad hoc reviewer for several journals. He is the Principal Investigator of funded research grants. Prof. Bei research interests include the analysis of immune response to tumor associated antigens (TAAs) (ErbB receptors, AFP, CEA, PSA) in cancer patients and cancer immunotherapy; the expression of TAAs in tumors and normal tissues; the production and characterization of monoclonal antibodies to viral proteins.Recently, he has been involved on studying the effect of natural compounds on cancer cell growth.
Analysis of immune response to tumor associated antigens (TAAs) (ErbB receptors, AFP, CEA, PSA) in cancer patients.
Cancer immunotherapy: anti-cancer vaccines and murine and recombinant Mabs development. Expression of TAAs in tumors and normal tissues.
Production and characterization of monoclonal antibodies to viral proteins.
Analysis of the effect of natural compounds on cancer cell growth.
Brian Wigdahl, Ph.D., is professor and chair of the Department of Microbiology & Immunology, director of the Institute for Molecular Medicine and Infectious Disease, and director of the institute’s Center for Molecular Virology and Translational Neuroscience. The research efforts of the Department and Institute center on the diagnosis, treatment, and prevention of infectious, oncogenic, and inflammatory disease with a cumulative extramural research commitment of just over $60 million. He also serves as the executive director of the interdisciplinary graduate program in molecular medicine. An internationally recognized molecular virologist, he focuses his research on the molecular mechanisms, treatment, and prevention of immunologic abnormalities, cancer, and progressive neurologic disorders caused by members of the retrovirus family. These include the human immunodeficiency virus and the human T cell leukemia virus type 1 (HTLV-1), the first human tumor virus discovered. In particular, efforts are focused on the prevention of HIV sexual transmission and the HIV-induced neurologic complications of HIV/AIDS. He has been funded by the National Institutes of Health for nearly 30 years, with total awards totaling more than $40 million. Current funding includes three NIH R01 research grants and a component of an NIH P30 grant. He is also Co-Director of a Interdisciplinary and Translational Research Training Program in NeuroAIDS designed for graduate students. His current total research commitment is approximately $6 million. He graduated from Augsburg College in Minneapolis and received his doctorate in microbiology from the Medical College of Wisconsin. A senior associate editor of the Journal of NeuroVirology, he also served as chair of the NIH NeuroAIDS and Other End-Organ Diseases Review Committee, served for six years as president of the International Society for NeuroVirology and currently serves as treasurer of the Society. He is the 2013 recipient Pioneer in Neurovirology Award presented in recognition of outstanding individual achievement in the field of neurovirology and awarded by the International Society for NeuroVirology.
Immunopathogenesis and neuropathogenesis of HIV-1 and HTLV-I infection, transcriptional regulation of retroviral expression, viral sequence diversity and correlations to disease, development of microbicidal agents.
Dennis M Gross, MS, PhDis the CEO, Treasurer and Professor of Pharmacology for the Pennsylvania Drug Discovery Institute and Professor of Experimental Therapeutics and Medicinal Chemistry at the Baruch S. Blumberg Institute of the Hepatitis B Foundation He is also Faculty in the Jefferson College of Biomedical Sciences and Associate Professor of Pharmacology & Experimental Therapeutics in the Sidney Kimmel Medical College of Thomas Jefferson University (TJU) and Adjunct Professor of Basic Sciences at The Commonwealth Medical College. He is a member of the National Visiting Committee for the Northeast Biomanufacturing Center and Collaborative. He recently retired from full-time status at TJU where he was the Associate Dean for Program Development and Assessment and Director for the Professional Science Masters Program, Associate Professor of Pharmacology & Experimental Therapeutics in the Jefferson Medical College and Associate Director for Curriculum for the TJU Post baccalaureate Pre-Professional Premed Program. Prior to this, he was at the Merck Research Labs for 29 years retiring in 2006 as Senior Director and Head of West Point Business Operations with overall responsibilities for capital planning and facilities in Pennsylvania, California and Massachusetts. He was also responsible for capital lab and office projects and operations oversight at Merck lab sites in Canada, Japan, Italy and the UK. In his career at Merck he held a number of positions ranging from bench scientist to head of computer resources, divisional data security administrator, manager of international strategic planning, M&A activities and liaison for basic research and clinical drug development in Japan working with Banyu Pharmaceuticals.
During his tenure at Merck, he also served as Adjunct Professor of Global Logistics in the School of Business and Industry of Florida A&M University. He has worked with the Center for Strategic & International Studies in Washington, DC on policy issues relating to biological weapons of mass destruction. He received his BA (1969) and MS(1970) from California State University Northridge and his PhD (1974) from UCLA pursuing a postdoctoral fellowshipat Tulane University School of Medicine in the Department of Pharmacology. He has also participated in executive education programs at Wharton, MIT and the Tufts School of Law and received NIMS and ICS certification from the FEMA Emergency Management Institute. He is a member of the American Association for Pharmaceutical Scientists, American Chemical Society, American Heart Association, Global STEM Alliance, History of Science Society, International Society for Pharmaceutical Engineering, Sigma Xi and the Sino-American Pharmaceutical Professionals Association.
Angiotensin converting enzyme inhibitors for hypertension; Vasodilators for renal failure; β-adrenergic blockers for ocular hypertension; Cardio selective β-adrenergic blockers for hypertension; Research and development of new drugs for hypertension and the renal/cardiovascular system; Biomedical computer and lab automation applications
Yi Qun Xiao, Ph.D., is Director of Biomarkers, Bioanalysis and Clinical Sciences at Envigo since September 2014. Prior to this position, he was Director of Immunology Department at MPI Research. Dr. Xiao has played a very important role in expansion of immunotoxicity and large molecule bioanalytical capabilities. In the past eight years, more than 400 non-GLP and GLP studies have been successfully conducted under Dr. Xiao’s supervision and management including PK, immunogenicity, neutralizing antibody assays, biomarkers, flow cytometry-based and cell-based immunotoxicity assays.
Dr. Xiao graduated from Beijing Medical University (Beijing University Health Sciences Center), China, and received his Master and Doctoral degrees of Pharmaceutical Sciences from Tohoku University, Japan. He started his professional career at Tianjin Lisheng Pharmaceutical Co., China, as a research scientist and the Director of Department of New Product Development thereafter. Dr. Xiao pursued postdoctoral research at National Jewish Health Center. Before he joined MPI Research, he was an instructor at the Division of Pulmonary Sciences and Critical Care Medicine at University of Colorado Health Sciences Center. Dr. Xiao has extensive academic, industrial and CRO experience in Immunology, Cell and Molecular Biology noted by recognition in peer reviewed publications such as Cell, Journal of Immunology and Journal of Biological Chemistry. He is currently an active member of AAI and AAPS, a peer reviewer of AAPS, Journal of Immunology, Journal of Immunological Method, MOJ Immunology and MOJ Cell Science & Report.
Immunoassay, Immunochemistry, Immunotoxicology, Immunotherapy, Cancer Immunotherapy, Autoimmunity and Inflammation.
Alaa Ahmed currently heads the Research unit at the faculty of Public Health & Tropical Medicine, and Direct the Medical Research Center Laboratories at Jazan University. He also is the CEO.CSO of immune Diagnostic Laboratories in Tempe, AZ. He is active member of the Arizona Bio industry group and serves as scientific board member for several life science and diagnostic companies in Europe and the US. He developed, validated, and introduced more than 900 new diagnostic tests into the diagnostic industry. He holds a Master degree in Clinical chemistry (Surrey, UK, 1985) and a PhD degree in Immunopathology (Glasgow University, 1989 where he discovered and characterized Vitronectin. He has supervised, collaborated and founded numerous studies, with more than 93 publications in peer reviewed journal sand book chapters. He is also an active member of several national and international disease study groups. Through his carrier, he supervised and trained numerous international students and colleagues. He serves also on the editorial boards of several prestigious journals. .
Pathophysiological mechanisms of immune diseases, including molecular, cellular and inflammatory responses of chronic diseases. Areas currently under investigation include autoimmunity, auto antibodies, cancer biology, inflammation, and viral immunity
Sachin Kumar Samuchiwal, Ph.D. in tuberculosis drug designing (International Centre for Genetic Engineering and Biotechnology, India) with one year postdoctoral training (Brigham and Women’s Hospital, Harvard Medical School, Boston) in studying prostaglandins and leukotrienes during respiratory virus infections, host response and onset of Asthma, and identification and characterization of a novel growth factor secreted by mast cells. Experience with small as well as large scaled protein purifications, proteinprotein interactions, peptide library synthesis, grant writing, and training graduate and post-graduate students.
Techniques of protein purification and protein-protein interaction, Host-pathogen interaction, targeting virulence determining proteins for therapeutics development
Abdel Omri obtained his PhD from Université de Montréal in 1996. After completing postdoctoral fellowships at McGill University and the University of Toronto (1996-1998), he spent more than 2 years as Research associate at NRC (institute of biological sciences in Ottawa) from 1998 to 2000. He is currently Full Professor in the Department of Chemistry and Biochemistry with a cross appointment to the Department of Biology, the Bio molecular Sciences PhD Programme, School of Rural and Northern Health PhD Programme. His research interests are focused on Lipid-based drug and vaccine delivery systems. His laboratory employs a multi-disciplinary approach to addressing the antimicrobial resistance to gram negative bacteria in cystic fibrosis patients and in medical devices implants. He is also involved in the education of undergraduate and graduate students through the coordination of several calendar courses in biochemistry, pharmacology and toxicology and pharmaceutical technology. In addition to research, He is actively involved in the research training of both undergraduate and graduate students. He has served in administrative capacities in several international scientific societies. He has published over 50 peer-reviewed research articles over his career on various aspects of drug delivery and targeting in addition to several published book chapters and books (2). He has served on a number of Editorial Boards and Granting Agencies in Canada and abroad. He has 2 patents.
Dr. Atilla Ertan earned his MD from the Ankara University Medical School in Turkey in 1963. Following completion of his fellowship in Gastroenterology at the Hospital of the University of Pennsylvania in 1971, he was professor of medicine at the Tulane University School of Medicine in New Orleans from 1980-90 where he was named Chief of the Gastroenterology Section from 1984-90 and Interim Chairman of Medicine Department from 1988-90. Then, he was Chief of the Gastroenterology Section at the Methodist Hospital/ Baylor College of Medicine (BCM) from 1990 to 2001. He was Clinical Professor of Medicine at both BCM as well as Weill-Cornell Medical College. He is now professor at the UT McGovern Medical School (UTMMS) and Director of the Ertan Digestive Disease Center (EDDC) of Excellence at the Memorial Hermann-Texas Medical Center (MH-TMC) since 2011. He has organized the Ertan Educational and Research Foundation with major contributions from the community since 2013. The A. Ertan Chair is established by the UTMMS and also, $1 million Chao Fund Endowed Directorship is established at the MH-TMC EDDC of Excellence in 2015.
Dr. Ertan has achieved national and international recognition as an outstanding clinical scientist, educator, researcher, and administrator in the field of gastroenterology. He has published over 170 articles in peer review journals, book chapters, books, and has received numerous awards and honors. He received the Medicine Science Award of 1992 by the Turkish Science and Technology Research Assembly, 1996 Best Gastroenterologist Award by the Crohn's and Colitis Foundation of America, and the 2003 Distinguished Clinician Award by the American Gastroenterology Association (AGA). In October 2003; he received the Master in Gastroenterology Award from the American College of Gastroenterology (ACG) and the Fellow by AGA in 2007. He has been named to the Top Doctor's in Houston and in the U.S. since 1995.
Dr. Ertan has been active in various national and international gastroenterology societies. For many years he served on the AGA's Education Committee(1994-97), the International Liaison Committee (1999-03), the ACG's International Relations Committee (Chair, International GI Training Subcommittee, 1994-98) and the Educational Affairs Committee (Chair 1999-01). He currently serves on the Editorial Boards of five different medical journals.
Dr. Ertan has a special interest and experience in the diagnosis and management of patients with inflammatory bowel diseases including Crohn disease, chronic ulcerative colitis, various microscopic colitides; biliary/pancreatic benign and malignant disorders, Barrett esophagus with dysplasia and early cancer plus these patients’ need for various advanced GI endoscopic diagnostic/therapeutic modalities. More information from: atillaertan.com.
Dr. William C Fanslow was a Scientific Director and Project Leader in the Vascular Biology Department at Immunex where he worked in various positions of increasing responsibility within research and development for 14 years (Cellular Immunology, Tumor Immunology and Immunobiology). He is currently a Scientific Executive Director at the Amgen Washington site where he was originally an investigator in the Hematology-Oncology Therapeutic area focusing on preclinical development of targeted therapeutics (LM, effector function-enhanced antibodies, ADC) and target discovery and now is a group leader in the Therapeutic Innovation Unit (TIU). In the TIU, He directs teams that focus on next generation ADC for both cancer and non-cancer indications, cyno autologous tumor implantation, cancer immunotherapy and induced pluripotent stem cells. He is a named inventor on over 50 issued US patents and multiple pending applications. He is the author or co-author on more than 100 peer-reviewed publications. He double majored in Chemistry and Biology earning his B.S degree with honors, in both disciplines, from Whitworth University. He received his Ph.D. in Biochemistry and Molecular Biology from the Department of Biochemistry and Cell Biology at Rice University. He did his post-doctoral work in the laboratory of Dr. Fred Rudolph at Rice University where he focused on the isolation and in vitro/in vivo functional characterization of placental immunoregulatory peptides/proteins.
Growth factor/ growth factor receptors, transplantation immunobiology, T cell function/adaptive immunity, immunotherapy, host defense against infectious disease, development of preclinical in vivo pharmacology disease models, regulation of vasculogenesis and angiogenesis, developing targeted biological anti-tumor therapies including antibody drug conjugates, Fc-enhanced monoclonal antibodies and bispecific antibodies. He has an ongoing interest in translational medicine, development of biomarkers and building the evidence for therapeutic biological impact in patients during the Phase 1 to the E2L transition. He is passionate about delivering impactful medicines to cancer patients and other patients with serious illness.
Dr. Joseph P Chandler, Ph.D a native of Trenton, NJ, he was awarded his BA in Biology from Gettysburg College (’72), Gettysburg, PA; his MS in Animal Science and Agricultural Biochemistry from the University of Delaware (‘76), Newark, DE; and, his Ph.D. in Immunology from the University of Connecticut (’81), Storrs, CT. After completing his Ph.D., he took a post-doctoral position at the Trudeau Institute, Saranac Lake, NY. In 1983, he became Scientific Director at Charles River Biotechnical Services in Wilmington, MA. There he established their monoclonal antibody production operation. In 1986, he became Director of Immunology at Ventrex Laboratories, Inc., Portland, ME. In this position, he oversaw the company’s cell culture media division and antibody purification laboratory for its in vitro diagnostic products.
He then founded Maine Biotechnology Services, Inc., in 1990, also based in Portland, and he has been the company’s President since its inception. Commencing in 1986, he became an adjunct professor at the University of Southern Maine, Portland, ME, where he has taught classes and mentored Masters of Science students. From 2009 to 2013, he was a member of the board of the Bioscience Association of Maine and was its treasurer during his tenure.
He resides in Durham, ME where he enjoys gardening and rearing orchids. He is an active theater-goer and has a son in the film industry in Los Angeles, CA.
Immunology, Monoclonal antibody technology, Recombinant protein technology, Antibody discovery and production
Nirmal Kumar Ganguly, M.D was formerly a Distinguished Biotechnology Research Professor, Department of Biotechnology, Government of India. He was formerly President of the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), as well as that of the Asian Institute of Public Health, Bhubaneswar, Odisha. He is the former Director General, Indian Council of Medical Research (ICMR), New Delhi; former Director, PGIMER (Chandigarh); and former Director, National Institute of Biologicals (Noida).
Prof. Ganguly has published more than 775 research papers and has supervised 130 Ph.D theses as Supervisor/Co-Supervisor. His major areas of research have been Tropical Diseases, Cardiovascular Diseases and Diarrhoeal Diseases. His interest encompasses the disciplines of Immunology, Biotechnology and Public Health. Prof. Ganguly is Fellow, Imperial College Faculty of Medicine, London; Royal College of Pathologists, London; International Academy of Cardiovascular Sciences, Canada; Third World Academy of Sciences, Italy; and International Medical Sciences Academy, New Delhi. He is also Fellow, National Academy of Medical Sciences, New Delhi; Indian National Science Academy, New Delhi; National Academy of Sciences, Allahabad; and the Indian Academy of Sciences, Bangalore.
He is Member of the Advisory Group, Cholera Vaccine Investment Case Preparation, International Vaccine Institute (IVI), Seoul, South Korea. He is also Member, Global Access Advisory Committee, University of Western Ontario, Canada; Worldwide Anti-malarial Resistance Network (WWARN), Centre for Tropical Medicine, University of Oxford, U.K., and Asian AIDS Vaccine Network Task Force, WHO, Geneva, Switzerland. He is Member, Editorial Board of Molecular and Cellular Biochemistry, Institute of Cardiovascular Sciences, University of Manitoba, Canada. He is Advisory Board Member, Grand Challenges (Canada). He is President, The Asian Conference on Diarrhoeal Diseases and Nutrition (ASCODD), Yogyakarta, Indonesia. Prof. Ganguly is Honorary Global Health Research Fellow and Adjunct Professor, Boston University, USA. He is also an Adjunct Professor of Environmental Health, School of Public Health, University of Minnesota, USA. He is also a Member of the Scientific Board, Grand Challenges, Bill & Melinda Gates Foundation. He has been appointed chairman of Vallabhbhai Patel Chest Institute-Stem Cell Committee. He is also advisor to Regional Director SEARO and is a member of Regional Task Force on Diseases Targeted for Elimination. He has been appointed as a member of Global Work Group of the Advisory Committee to the Director (ACD) of Center for Disease Control (CDC), Atlanta, USA. He is also selected as Global Infectious Disease External Advisory Board, Sanofi Pasteur, June 2015. In 2016 he has been selected by Regional Director SEARO as Member Advisory Board of WHO South-East Asia Journal of Public Health (SEAJPH) and editorial board member for MOJ Immunology. He is Chairman, Expert Advisory Group for Global Health Strategies implemented project on safe injection practices and Chairman, Indraprastha Apollo Hospital Ethics Committee. He has also been selected as Member, IVI Scientific Advisory Board and a Member of Sub group of Chief Minister's Advisory Council, Rajasthan state, India.
In 2015 he has been selected for the award of Helmholtz International Fellow by Helmholtz Center for Infection Research, Germany for significant contribution to the field of infectious diseases. He has been awarded distinguished scientific award from Yakult, Japan in 2016. He has received 119 Awards, including 8 International and 111 National Awards. He has been honoured with the prestigious Padma Bhushan Award by Her Excellency, the President of India on 26th January, 2008 in the field of “Medicine”.
Biotechnology, Immunology and Medicine
Institute of Immunobiology and Human Genetics
Republic of Macedonia
Mirko Spiroski is the founder and Editor-in-Chief of the Macedonian Journal of Medical Sciences. He is a graduate of the Skopje Faculty of Medicine (1972), where he later obtained his MSc (1978), and PhD (1989) degrees. He is the founder and first Director of the Institute of Immunobiology and Human Genetics at the Faculty of Medicine in Skopje and acts as a tutor of the Medical Scientific Club "Acad. Dimitar Arsov". He introduced several subjects in the curricula at the Faculties of Medicine (Immunology and Human genetics), Natural Sciences (Immunochemistry with basic immunology, Biochemistry-3, Immunogenetics), Physical Education (Genetics in sport), and in the Master of Sciences postgraduate program in Public Health (Public health genetics). His research interest is immunology, but he has also published in the fields of molecular anthropology and human genetics. He was Secretary general and Deputy Editor-in-Chief of the journal Godishen zbornik na Medicinski Fakultet Skopje, and Editor-in-Chief of the Macedonian Journal of Medicine.
Immunochemistry with basic immunology; Biochemistry-3; Immunogenetics; Immunology and Human genetics
Dr. David W Anderson has a Ph.D. in Medical Microbiology and Immunology from the University of Missouri-Columbia. He has over 30 years of experience in biopharmaceutical drug discovery and development with extensive research & management experience in all phases from target discovery/validation to clinical translational proof-of-concept. He was a co-founder of Signal Pharmaceuticals (acquired by Celgene Corporation) and Proprius Pharmaceuticals (acquired by Cypress); has helped fund and establish the technology for starting 6 biotechnology companies and currently serves as a consultant for several firms. He held senior positions at Ignyta (Current VP Cancer Biology), Eclipse Therapeutics (acquired by Bionomics), Proprius Pharmaceuticals, Celgene Corporation, Johnson & Johnson, and Monsanto/ Searle. He was a leader or on teams responsible for the development of 8 INDs, 2 NDAs and 5 drugs approved by the FDA, including J&J’s Procrit® (erythropoietin), a product that achieved peak annual sales of over $4 billion, Leustatin®, and Revlimid® for oncology,Zubrin® for veterinary arthritis, and Surfaxin® for respiratory disorders. He has held academic positions at the University of Colorado Health Sciences Center and The Scripps Research Institution. He has organized, chaired, and spoken at international conferences focused on discovery and development of novel anti-inflammatory/immunomodulatory and cancer drugs, and has refereed articles for peer-reviewed journals such as Science and The Journal of Rheumatology. He also has an outstanding record of scientific publications and presentations (32 peer reviewed publications and over 50 presentations/abstracts), and has received a number of research awards and five patents for his innovative research.
Project Portfolio Management; Line Management; Virtual Company Management; Problem Solving; Scientific & Business Acumen; Biotechnology & Pharmaceutical Industry; Technology; Assessment/Integration; Target Discovery/Validation; Small Molecule & Biologicals; Pharmaceutical Company and Academic Collaborations
Dr. George F. Babcock received his PhD from the University of Nebraska, College of Medicine,Omaha Nebraska. He is currently Professor of Surgery and adjunct Professor of Cancer and Cell Biology at the University of Cincinnati, College of Medicine. He is also the Deputy Director for Research at Shriners Hospitals for Children-Cincinnati, OH. He is chair of the universities Institutional Animal Care and Use Committee. He has been on the editorial board of Burns, Journal of Experimental and Clinical Cancer Research, The Journal of Nutritional Immunology and Biochemical Pharmacology. Additional he has reviewed manuscripts for 26 other journals. He is an active researcher with over 160 peer reviewed papers, 17 book chapters, and the series editor for 4 books and the edition editor for 1. Dr. Babcock is a member of 17 professional societies. He has served on NIH and DOD study sections and is currently the chair of the Military Infectious Diseases Research Program (MIDRP) study section.
Immunology, Microbiology and Inflammation. More specifically the lab is interested in the effects of burns and other trauma on the immune response with an emphasis on the innate immune system. Related to this is an interest in the regulation of apoptosis and adhesion molecules in neutrophils especially after burn trauma.The onset of infections and alterations in wound healing following thermal injury are also being investigated. In addition, area of research include the development of treatments for infected burn wounds especially the use of new anti-microbial agents and the use of biological response modifiers, research into modulation of the immune system by microvesicles and by nutritional manipulation of the host following burn injury, an examination of the immunotoxicolgy of agents encountered in the environment and the development and use of flow and image cytometry to measure biological responses.
Jianhua Luo been studying molecular pathology related to human malignancies in the last 23 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 13 years, he has been largely focusing on genetic and molecular mechanism of human prostate and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MT1h and GPC3. He has characterized several signaling pathways that play critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 egigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, and AR-MCM7 oncogenic pathway. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array to analyze prostate cancer. Recently, Dr. Luo’s group found that patterns of copy number variants of certain specific genome loci are predictive of prostate cancer clinical outcomes, regardless tissue origin. Overall, these findings advance our understanding on how cancer develops and behaves and lay down the foundation for better future diagnosis and treatment of human malignancies.
Research interest involve identifying new tumor suppressor genes, oncogenes and tumor markers in prostate cancer and hepatocellular carcinoma using high throughput and comprehensive analyses. Subsequently, we will direct our effort to evaluate the prognostic values of these genes and markers in making early diagnosis of these malignancies and serving as drug targets for cancer prevention program. As the Director of High Throughput Genome Center, he has collaborated extensively with faculty members in the UPMC and University campuses to use high throughput genome sequencing and high throughput microarray analyses to develop tests for molecular pathology and to investigate novel mechanisms for signal transduction andidentifying markers for human diseases.
Azzam A Maghazachi received a master degree from NYU Medical School and a PhD degree in Immunology from the University of Manitoba in 1984. He did post-doctoral fellowships with Dr. Julia Phillips-Quagliata at NYU Medical School and Dr. Ronald B. Herberman at the Pittsburgh Cancer Institute. Between 1988-2005, he held several senior positions at various institutes and universities in the USA, Canada and Norway. In 2005, he was the director of research at Bio-Quant, Inc. in San Diego, and since 2007 is a professor of Physiology in the faculty of Medicine at the University of Oslo. He and his group were the first to identify all chemokine receptors on NK cells and were the first to examine the biological activities of chemokines on these cells. Later, they identified lysophospholipids and oxidized lipids receptors on NK cells and investigated the effects of these lipids. They also discovered a new subset of NK cells that secrete both IL-17 and IFN-g, and designated them as NK17/NK1 cells. His group is currently investigating the effects of drugs used to treat multiple sclerosis such as Tecfidera, Copaxone, Gilenya, Natalizumab and Vitamin D3, among others on various immune cells which include but not restricted to NK cells, dendritic cells and T cells. He published more than 100 papers and book chapters and is an editor on 12 medical journals.
Autoimmune diseases, Multiple sclerosis, Cancer, Hematology, Immunology, Drug mechanisms of action (MOA), Chemokines, Lipids
Dr. Rimas Orentas is an Associate Scientist in the Pediatric Oncology Branch of the National Cancer Institute's Center for Cancer Research (CCR), on the NIH campus in Bethesda, MD. After completing his PhD at Johns Hopkins University, he rose to the rank of Associate Professor at the Medical College of Wisconsin, with a primary appointment in the Hematology-Oncology Section of the Department of Pediatrics, and joint appointments in the Department of Medicine, and the Department of Microbiology and Molecular Genetics. His research there focused on cell-based vaccines for neuroblastoma, and on the immune response to EBV-associated cancers. How a tumor arises in the context of a healthy immune system, and why tumor vaccines fail to protect tumor-bearing hosts remain central interests. He is deeply interested in the genetic engineering of the T lymphocyte response, and cloned and expressed a number of TCRs specific for EBV latency antigens using retroviral and then lentiviral gene vectors. He then joined Lentigen Corp., and served as the Director of Oncology and Biotherapeutics for two years, prior to his arrival at the NIH. Current interests remain focused on the adoptive immunotherapy of cancer, specifically using T cells engineered to express chimeric antigen receptors (CARs). In association with these studies, bioinformatic analysis of gene expression patterns in normal and cancer tissue is being used to identify to cell surface targets for antibody or T-cell based immunotherapy.
Adoptive immunotherapy; T-cell biology; Lentiviral and Retroviral gene vectors; cytotoxic T cells; Genetic engineering of T cells; Pediatric cancer; Cancer vaccines; CARs (chimeric antigen receptors)
Dr. Joseph Murphy, Ph.D., he has more than 20 years experience in biological research in both academia and the biotechnology industry. In 2011 he was appointed Director of Cancer Therapeutics and Immunology, Southern Research Institute, Birmingham, Alabama. Prior to that he was he was a Lecturer and Senior Research Scientist Trinity College, University of Dublin, Ireland. Previously, he served as Founder/Managing Director of Emmerex Limited, a company focused on developing an immune-based therapy for cancer. He holds a Bachelor's of Science degree in Mathematics, Experimental Physics, and Biology from the National University of Ireland. He earned his Doctorate of Philosophy from the Department of Biological Sciences, University of Salford, United Kingdom. He conducted post-doctoral work at INSERM U331, the Institute Pasteur, Lyon, France and Stanford University, CA. He has written and/or contributed to more than 100 scientific abstracts and articles. He has served as a reviewer for Clinical Medicine/Oncology, Prostate Cancer Foundation of Australia, Clinical Medicine/Cardiology, International Journal of Cancer, and the Journal of Medical Genetics and Genomics.
Symbiotic relationship between cancer and angiogenesis; Immune modulation as a means of anti-cancer and anti-angiogenic therapy; Microarray analysis and target validation; Cyclooxygenase mediation of angiogenesis and cancer; Integrin modulation of angiogenesis; Endothelial cell adhesion molecules involved in leukocyte adhesion and angiogenesis; Enzyme-linked immunosorbent assay development for early detection of cancer
Dr. Henry Hongrong Cai Born in the country side of Yancheng in the Northern Jiangsu Province of China, He is a U.S. certified MD who completed postdoctoral training at the University of Maryland Medical School, specialized in oncology/internal medicine. His research project related to transgenic mouse as a model for breast cancer oncogenesis. He also completed his Master's in Immunology at the Peking Union Medical College in 1990 and Master's in Biochemistry at the University of Maryland, Baltimore in 1998. He has a long time experience working in drug development, especially the development of vaccines and therapeutic monoclonal antibodies in aclinical, academic, and pharmaceutical environment. In recent years he focuses on pharmacovigilance practice in clinical trial and post marketing setting as a medical director in pharmacovigilance and drug safety with EMD Serono and InVentive Health Clinical. He is the first who indicated signal detection activity not only helps to maintain the safety profile of the drug, but also can be used to direct the modification of the drug, especially therapeutic antibody (molecular pharmacovigilance).
Walter J. Storkus received his B.A. from Brandeis University (Mathematics, Biochemistry) in 1981 and his Ph.D. from Duke University in 1986. After completing a fellowship at Duke University, he became Assistant Professor of Surgery at the University of Pittsburgh in 1991. He is currently Professor of Dermatology and Immunology at the University of Pittsburgh School of Medicine. His research focus is directed towards a better understanding of tumor immunobiology and designing effective immunotherapies for the treatment of cancer based on translational murine models and human in vitro studies. Such modalities have included dendritic cell (DC)-based vaccines, cytokine gene-modified DC injected directly into tumor lesions and combinational approaches integrating agents that modulate tumor cell immune recognition (i.e. HSP90 inhibitors) or alter the balance or Type-1 versus regulatory immunity in the tumor microenvironment (i.e. sunitinib). Most recently, he has focused on the development of vaccines targeting of tumor-associated vascular antigens to facilitate tumor regression even in cases where cancer cells cannot be directly recognized by the adaptive immune system.
Dr. Aggarwal is a Ransom Horne, Jr. Distinguished Professor of Cancer Research, Professor of Cancer Medicine, Professor of Immunology, Professor of Biochemistry and Professor of Experimental Therapeutics, and Chief, Cytokine Research Section, in the Department of Experimental Therapeutics at the University of Texas M. D. Anderson Cancer Center, Houston, Texas. He also serves as member of the University of Texas Graduate School of Biomedical Sciences, Houston, and as an Adjunct Professor atAlbert B. Alkek Institute of Biosciences and Technology, Texas A&M University, Houston, Texas and member in various Institutional committees of MDACC. Dr. Aggarwal earned his Ph. D. in Biochemistry from the University of California, Berkeley, received his Post-Doctoral training from the Hormone Research Laboratory at the University of California Medical Center, San Francisco. He then started his career with Genentech Inc where he worked for almost ten years and his work lead to the discovery of TNF- aand TNF-b, an essential component of the immune system; and identification of their receptors. In 1989, Dr. Aggarwal was recruited as a Professor of Medicine and of Clinical Immunology & Biological Therapy, Chief of the Cytokine Research section at the University of Texas M. D. Anderson Cancer Center. Since then Dr Aggarwal has been investigating the “Role of Inflammatory Pathways Mediated through TNF, NF-kappaB and STAT3, for the Prevention and Therapy of Cancer and other Chronic Diseases”. While searching for novel and safe anti-inflammatory agents, his group has identified more than 50 novel compounds from dietary sources and from Traditional Medicine that interrupt these cell-signaling pathways. These agents have been tested in various animal models and some of them are now in Clinical Trials. He has published more than 600 papers in peer-reviewed international journals (including Science, Nature, Cancer Cell, PNAS, Journal of Experimental Medicine, Blood, JBC, Cancer Research, Journal of Immunology), invited reviews and book chapters. Dr. Aggarwal is inventor/co-inventor on over 33 patents. He has been listed as one of the most highly cited scientist in the world by ISI since 2001; and has been included in ISI Highly Cited among most highly cited authors in Immunology category. He has also been listed as one of the top 25 researchers in the area of “Apoptosis” in the World. His papers exhibit very high-citation index (almost TEN exceed 1000). His overall citation is now at 75,900 with an H-index of 120.
Dr. Aggarwal is currently a member of the editorial boards of 24 international Journals and served as a reviewer for more than 160 Journals, various grant proposals and of several Ph.D. theses. Dr. Aggarwal has edited 12 books and served as Guest editor for special issues from Biotherapy, Cancer Letters and Current Opinion in Pharmacology. He has trained over 80 Post-doctoral Fellows and Visiting Professors from around the world. He has co-organized and served as member in many International and National Conferences/ Symposia; has started International Society of Translational Cancer Research and has delivered over 350 lectures/seminars/keynote talks in more than 50 countries. He has recently authored a book “Healing Spices” released in January, 2011 by Sterling; and is already a best-seller. Dr. Aggarwal has received numerous awards including • ARTOI Award, Association for Research Integrated Oncology Therapies, Rome, Italy, 2012; •2011 James A. Duke Award Excellence in Botanical Literature Award, American Botanical Council, Anaheim, California, 2012; World Congress Science Prize from Oxygen Club ofCalifornia 2010; Excellence in Research Award of McCormick Research Institute from the AmericanAssociation of Nutrition, 2008, Outstanding ScientistAward from the American Association of Indian Scientists in Cancer Research, 2006, Ranbaxy Award for Outstanding Scientist of the year, 2004.
Dr. Andrew D Yurochko is an Assistant Director of Research, Arthritis and Rheumatology Center of Excellence and Professor of Microbiology and Immunology at LSU Health Sciences Center-Shreveport, USA. He completed his graduation in Biochemistry and Biology, and a Minor in Chemistryat Virginia Polytechnic Institute and State University. He received his PhD in Immunology (Department of Biology) from Virginia Tech. Professional career started in 1985 as Graduate Teaching Assistantship: Department of Biology, Virginia Tech. In 1990-1992 he got National Research Service Award Postdoctoral Training Fellowship from Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill. He received many Awards and Honors in his career and published many Review Articles/Book Chapters in International journals.
Pathobiology of human cytomegalovirus infection, Human cytomegalovirus is a leading infectious cause of congenital abnormalities, transplant associated disease, and other serious diseases in immunocompromised patients. It also is a strong risk factor in the development of various cardiovascular diseases and may be linked to some types of human cancers. His laboratory has focused on understanding the link between viral dissemination and the establishment of life-long viral persistence to viral-mediated disease.
Dr. Burn is a successful senior scientist, leader and business executive with a lifelong mission, focus and passion of improving the human condition by delivering products, cures and care to patients and their families. As a senior executive with extensive global industry and international management experience, he has a proven track record of success in Academia, Pharmaceutical R&D, Biotech, Not-for-Profit and Integrated Health Care organizations. He designed, implemented and led multiple patient-centric programs which resulted in successful basic and translational research and development programs, in the pharmaceutical, nutrition, diagnostic, personalized medicine, treatment and cure areas.
With over 30 years of experience in pharmaceutical and nutritional R&D and academia, he spearheaded many programs, from the gene to the clinics and through marketed products in the Autoimmunity, Inflammation, Endocrine, Metabolic Diseases, Cardiovascular, Renal, Bone, Musculoskeletal, Neuroscience, Dermatology, Oncology and Women’s Health therapeutic areas. Under his leadership multiple programs resulted in the successful identification of clinical candidate molecules, their evaluation in humans and subsequent market introduction.
Most recently Dr. Burn served as Professor of Pediatrics at the Sanford School of Medicine of The University of South Dakota and as Scientific Founder, CEO and President of Metabolic Health & Fitness. In addition, he was the acting Chair and Director of The Sanford Project at Sanford Health, the largest rural health care provider in the US. He also serves on several company Boards and Scientific Advisory Boards of Universities, Biotech companies and Government agencies.
Autoimmune Diseases, Immunomodulation, Immunotherapy, Inflammatory Diseases, Regeneration, Type 1 Diabetes, Type 2 diabetes, Obesity, Drug Discovery and Development, Translational Research, Clinical Research, Clinical Development, Clinical Trials, Translational Medicine, Personalized Medicine, Etiology and Pathophysiology of Immune Diseases, Molecular, Cellular and Inflammatory Responses of Immune Diseases
Dr. Antonio Scardino has the MD degree in Rome in 1994. Postdoc fellow at the Cancer Institute of N.I.H., in Bethesda, from 1995 to 1997, he studied T cell receptor peptide mimicry and MHC class-I molecules in human APCs. In 1997 he wins a PhD grant in cancer immunology at Pasteur Institute, in France, where graduates in 2000 with a PhD thesis on the discovery of criptic epitopes for cancer vaccines. These studies led to patents and clinical trials of Her-2/neu and hTERT criptic epitopes asvaccine therapy for breast cancer. Back in Italy in 2001, He is senior scientists at the Instituteof Medicine, in Rome. He shifts his interests on primordial causes of immunity impairement in humans, performing clinical experiences with HIV patients and starting a collaboration with a psychiatric center for toxicomanias, in order to study effects of stress and behaviour on to immune system. He has published 16 articles on immunology and anticancer vaccination issues and collaborates with italian national newspapers for divulgative articles and books. He currently serves as a clinical physician in the Urbino hospital, as immunologist: in collaboration with psychiatrist and psychologists, works on psychoneuroimmunology issues and projects, studying effects of stress onto thehormon release and immune response in humans.
Hypnotherapy effects on Cortisol levels in plasma and saliva of normal volunteers and consenting psychiatric patients. He is intrigued by psychoneuroimmunology works focused on relationship between stress, behaviour and immunity.
Dr. John Gordonhas more than 250 published papers (primarily around human B cells and their malignancies) and is among the top 0.5% of published scientists as acknowledged by his inclusion in the elite club of ISI's 'Most Highly Cited Researchers'. As of July last year (2013), he retired from the University of Birmingham while keeping (Emeritus) Professor status. This has freed him to develop and progress the expanding and increasingly exciting opportunities within Celentyx Ltd.
For the past decade or so, he has been pioneering the field of Neuro-Immuno-Pharmacology. His success in promoting this concept (namely that immune cells express multiple components more traditionally associated with the CNS and as such offer novel targets in immuno/cancer therapy) has led to worldwide media interest (e.g. Google ‘Gordon, Lymphoma and/or Cancer, Prozac and/or Ecstasy’) and academic recognition as evidenced by pioneering research papers in high impact journals, the editing of associated monographs, and invites to international conferences. In 2004 he combined his own expertise with that of Neuropharmacologist Nick Barnes to create Celentyx Ltd, a high-end service CRO offering bespoke Human Immuno-Profiling for Pharma & Biotech.
Kameshwar Singh received his degree in Veterinary Medicine from Ranchi College of Veterinary Science and Animal Husbandry, Ranchi, India in 1968-74. He also received specialized Master of Veterinary Science in Veterinary Bacteriology (including Virology, Mycology and Immunology) degree in 1974-76 from Indian Veterinary Research Institute (Ruhelkhand University), Bareilly, India. He began his carrier at the Industrial Toxicology Research Center (CSIR, Govt. of India), Lucknow, India (1977-1992), where became the head of Preventive Toxicology Division and Environmental Microbiology Division. He was selected Raman Research Fellow from CSIR and received postdoctoral training at Department of Surgical Oncology, UCLA Center for Health Sciences, University of California, Los Angeles in 1989. He subsequently moved to the Institute of Chemical Toxicology, Wayne State University, Detroit, MI, where served as Senior Research Associate and later worked as Research Scientist in Immunology and Microbiology Division, School of Medicine, Wayne State University (1993-2004). He moved to Environmental Medicine Division, School of Medicine and Dentistry, University of Rochester in 2004 and joined as Faculty. Dr. Singh has published more than 75 papers and two books. Currently, he is member of Editorial Board of several research journals including Stem Cell Biology and Research, and Veterinary World.
Evan B Siegel founded Ground Zero Pharmaceuticals (GZP) in 1999 from his consulting firm, Ground Zero Strategics, Ltd. He currently serves as its President and CEO, and is also the Chairman of the Board. Prior to GZP Dr. Siegel was CEO of OXO Chemie Inc., Vice President, Regulatory Affairs and Bioethics for Medical Science Systems, Inc (now Interleukin Genetics), and Director of Regulatory Consulting Services and Principal Regulatory Scientist for Quintiles, Inc., North Carolina. He has held several other regulatory and executive positions at Astra and Syntex, and was a Toxicology Reviewer at the US Food and Drug Administration and Supervising Toxicologist, Food and Drug Branch of the California Department of Health Services. He has Master of Philosophy and Doctor of Philosophy degrees in Virology and Molecular Biology, a Master of Science in Health Physics and Radiological Health, and a Bachelor’s degree in Physics. He is presently an Adjunct Professor in the School of Pharmacy and Centre for Integrated Preclinical Drug Development, University of Queensland, Australia, and a member of the Biotechnology Advisory Subcommittee, Council of Economic Development, State of California. He is the editor of a book on combination products, and author of several book chapters, a number of research papers, and numerous presentations.
Client Programs in Immunotherapy; Immunoncology Therapeutics; Cancer Vaccines
Dr. Laurie M Erickson has are a broad range of professional experiences in Life Sciences and Molecular Biology, Her professional career has spanned 30 years of both academic and industry experience. From field studies in population genetics of white-tailed deer to molecular genetics contributions to the Human Genome Project.
She received her undergraduate degree in Zoology from Michigan State University, her Master’s degree from Texas Tech University and her PhD in Genetics from the University of Wisconsin in 1993. Her advisor was Dr. Oliver Smithies, Nobel Prize-winner in Physiology or Medicine in 2007. Post-graduate work in genomics and evolution was done at the University of North Carolina at Chapel Hill with Dr. Nobuyo Maeda, Dr. Marshall Edgell and Dr. Cora-Jean Edgell.
She entered the pharmaceutical industry as a senior scientist at Fujisawa Research Institute of America and rose to the position of Manager, Transplantation Immunology in Astellas Research Institute of America, studying the mechanisms of graft rejection and immunosuppression. She has worked in many cutting-edge fields of biology such as cloning, gene expression, embryonic stem cells, adult stem cells and personalized medicine.
Currently she is an adjunct professor at National Louis University in Chicago, IL, where she promotes science education in the US by training the next generation of science teachers.
The immunological mechanisms of acute and chronic graft rejection, the mechanisms of immunosuppressive drugs, the culture and differentiation of adult stem cells, the use of adult stem cells for personalized medicine, and the effects of transposable elements on genome and gene family evolution.
Dr. John L Dzuris has sixteen years diverse experience in drug discovery and translational research. He has extensively applied immunological and molecular approaches to study and identify different classes of therapeutics for infectious diseases, oncology and autoimmune diseases. He received his B.S. degree in Microbiology in 1983 from the Ohio State University, and in 1987 received his M.S. degree in Microbiology from Louisiana State University. He then attended Temple University School of Medicine in Philadelphia, PA receiving his Ph.D. in 1994 in the Department of Microbiology and Immunology. There his studies concentrated on retroviral escape from host immune responses. His study of retroviral and host immune response interactions continued with his Postdoctoral training at the University of Pennsylvania School of Medicine in Philadelphia, PA in the Department of Microbiology. He then joined the staff at Epimmune, Inc. in San Diego, CA in 1998 where he worked to develop DNA and peptide based vaccines for oncology and infectious diseases. His work at Epimmune also determined similarities that exist between human and non-human primate immune responses which could be used as a model for pre-clinical evaluation of vaccine efficacy. In 2001, he joined the staff at Wyeth Corporation as a Senior Scientist in the Department of Viral Immunology in Pearl River, NY conducting viral vaccine discovery research. He was then recruited to join Genzyme Corporation in 2002 as a Senior Scientist to help discover and develop vaccines for oncology and infectious diseases. As an Associate Director of the Cellular Immunology group that he established in Discovery Research, he spent nearly 10 years at Genzyme. His work focused on identifying small molecule drugs and biotherapeutics, including peptides/proteins, for immune modulation in transplant and autoimmune disease and the identification of new targets and biomarkers using a proteomic platform. Currently, he is Director of Immunology-Lab Head at ImmusanT Inc. engaged in pre-clinical and clinical research evaluating a vaccine for celiac disease.
Development of small molecule drugs and biotherapeutics for immune modulation in transplant and autoimmune disease, and the identification of new targets and biomarkers. Immunology, Immunotherapy, T-Lymphocytes, Autoimmunity, T Regulatory Cells, Peptide/Protein Therapeutics, Proteomics, Epitope Identification, Assay Development, Clinical Development
Sherven Sharma is Professor of Medicine at David Geffen School of Medicine at UCLA and Director of Gene Medicine Laboratory at the VAGLAHS. In seminal studies, his laboratory defined the role of therapeutic cytokines in augmenting anti-tumor immunity in novel genetic immunotherapy studies. His laboratory was the first to use dendritic cells (DC) as a therapeutic delivery vehicle for cytokine or chemokine genes against lung cancer. He developed the concept of intratumoral injection of these gene modified DC and documented that this intervention led to systemic anti-tumor responses. In collaboration with both VA and UCLA clinical investigators he brought this concept forward to a clinical trial in which patients received chemokine transduced autologous DC in a phase 1 clinical trial for lung cancer. He has published over 150 articles in peer reviewed journals and received many peer-reviewed grants for his research including those from federal funding agencies including the Veteran s Administration, the National Cancer Institute, and the Department of Defense. He has been invited to give presentations at national and international meetings. Consistent with his reputation as a leader in his field, he has participated in study sections for several organizations, including the NIH, the Department of Defense, and the Veteran s Administration. He is a recognized authority in tumor immunology and tumor immunotherapy and serves on the Editorial board of 6 journals.
Mechanisms in the tumor microenvironment that evade host responses and promote and maintain lung tumor growth. Knowledge gained from tumor host interactions is utilized for the development of novel immune strategies for lung cancer therapy.
Dr. Peter H. Lapchak trained at world-renowned Universities. During his postdoctoral training in the Division of Surgical Research at the University of Massachusetts Medical School, he studied the role of apoptosis by TNFR family members in mononuclear cells from trauma patients. This was followed by a postdoctoral research position in the Division of Nephrology at Children’s Hospital in Boston, Then he moved to the Brigham and Women’s Hospital, Boston where he was an Instructor in Surgery (Immunology) in the Department of Surgery. He joined the Rheumatology Division, Beth Israel Deaconess Medical Center, Boston. He developed an independent research program to study the contribution of platelets in local and remote tissue damage following mesenteric ischemia/reperfusion (I/R).
Immunology and inflammation and include identifying specific mechanisms by which platelets may modulate either innate or adaptive immunity. His research focus has been on platelets as immune cells and their contribution in the host response to systemic and organ-specific trauma. His research also focused on the role of platelets (and their products) on villi and lung tissue damage after mesenteric I/R. He would like to continue this research and extend his research findings to inflammatory bowel disease in which platelets have already been identified as contributors to the inflammatory response. He is interested in determining which cytokines or cytokine networks contribute to villi damage after mesenteric I/R. A few candidate cytokines have already been identified that bridge platelets to lymphocyte subsets. He would also like to further identify biomarkers of intestinal injury thus “bridging the bench to the bedside”. His research also identified potential contributors to remote (lung injury) which he would like to continue. Pursuing this research avenue may address current questions related to TRALI (transfusion-related acute lung injury).
Dr. Laurent Sabbagh is an Adjunct Professor in the Department of Microbiology, Infectiology and Immunology at University of Montreal and Research Scientist at Vertex Pharmaceuticals (Canada) Inc. After completing his PhD at McGill University he pursued a first post-doctoral fellowship at the Ontario Cancer Institute researching thymic development and T cell signaling. He subsequently moved on to the University of Toronto for a Senior fellowship working on elucidating novel signaling pathways downstream of TNF receptors and their implication in CD8 memory T cells maintenance. He then joined the hematology-oncology group at the research centre of Maisonneuve-Rosemont Hospital as a principle investigator and assistant professor at University of Montreal at the Faculty of Medicine within the Department of Microbiology and Immunology. His research there focused on the role of TNF receptor signaling in the survival of lymphocytes and their contribution to hematological malignancies. Current interests remain focused on TNF receptor signaling in inflammation and hematological malignancies. In addition, his work is focused on biomarker identification in inflammatory bowel disease and the impact of pharmacological agents on immune responses.
Immunological memory; T cell biology; Leukemia and lymphoma; Immunomodulation; Inflammation; TNF receptor signaling
Ryan Fiorini is a President and Chief Executive Officer of Perle Bioscience. He received his Ph.D. in Immunology and Microbiology from the Medical University of South Carolina (MUSC) in Charleston in 2005. His Ph.D. thesis was focused on improving the donor pool for solid organ transplants, specifically liver and kidney. He later received his M.B.A. from the Citadel in 2007 and a Masters of Hospital Administration (M.H.A.) from the Medical University in 2008. After receiving his PhD, he managed the tech transfer office for the Medical University of South Carolina (~$250MM research expenditures per year), consisting of approximately 100+ Invention Disclosures and 30+ patent filings per year. At MUSC, Fiorini analyzed all technologies, filed patent applications, assisted faculty start-up companies off the ground and out-licensed technologies to corporate partners.
In 2010, he founded Immunologix, Inc., a company built on a specialized platform that transformed naïve B-cells to produce 100% human monoclonal antibodies against multiple target antigens. From the company’s commencement in September 2009 through its acquisition by Intrexon Corporation (NYSE: XON) in October 2011, he served as the Founder and Chief Operating Officer. After the acquisition by Intrexon, he served as the Vice President of Antibody Development until transitioning into the role of Vice President of Therapeutics Business Development working directly for Intrexon CEO and biotech billionaire, Randal J. (R.J.) Kirk. He left Intrexon in April 2013 to spend more time looking for “the next” start-up opportunity, building his biotech consulting company and spending time with his family.
He has held adjunct faculty positions at both Trident Technical College and the College of Charleston Department of Biology. He previously served as the Vice President of the Palmetto Biotechnology Alliance Board of Directors from 2007-2009 and was designated by the Charleston Business Journal as one of the “Forty Under Forty” in 2010 in recognition of professional success and community involvement. In August 2014, He was accepted into the Society of International Business Fellows (SIBF). He serves on the Board of Directors for SIBF and the Executive Leadership Committee for the American Heart Association in South Carolina.
Determining the mechanism behind currently unknown etiology of various immune diseases;
Specifically, adaptive immunity with the production of antibodies from B-cells as well as autoimmune diseases such as type 1 diabetes;
Current project is conducting clinical trials on a late stage product to allow type 1 diabetic patients to become insulin independent (no longer need exogenous insulin injections or pump)
Dr. Josep Bassaganya Riera lead the Nutritional Immunology and Molecular Medicine Laboratory (NIMML, www.nimml.org) at the Virginia Bioinformatics Institute (VBI), which is a multi-PI research laboratory working at the interface of immunology, bioinformatics, computational modeling and inflammation. His group has been conducting mucosal immunology-related research for the last 15 years, and have published over 85 papers on the immunoregulatory properties during infectious inflammatory and immune-mediated diseases. Previous research from his group resulted in seminal discoveries regarding the immune modulatory and anti-inflammatory effects of conjugated linoleic acid and abscisic acid, with derivatives of these compounds being pursued as anti-inflammatory therapeutics. He is the Director of the Center for Modeling Immunity to Enteric Pathogens (www.modelingimmunity.org), a NIAID-funded Center under the Modeling Immunity for Biodefense (MIB) Program with the mission of understanding at the systems level the mechanisms of action underlying immune responses to enteric pathogens. MIEP has combined computational modeling and bioinformatics studies with immunology experimentation to characterize the mechanisms of immunoregulation underlying immune responses to gastroenteric pathogens. These approaches have resulted in the identification of novel disease biomarkers and therapeutic targets for immune-mediated and infectious diseases.
Computational Immunology; Nutritional Immunology; Drug Development; Multiscale Modeling
Dr. Frank A Redegeld studied Pharmacochemistry at the Free University, Amsterdam. He obtained his PhD at the Department of Pharmacology, Fac. Pharmacy, Utrecht University (1989). He received a Fogarty Fellowship to work as a postdoctoral researcher (1989-1992) at the Laboratory of Immunology, NIAID at the National Institutes of Health, Bethesda, USA (PI: M.V. Sitkovsky). As a recipient of a KNAW Fellowship (1992-1997) he returned to the Utrecht University (Dept. Pharmacology, Fac. Pharmacy, Utrecht University). In 1997 he became an assistant professor and in 2002 associate professor at the same department. In 2012, he spent a 6 month sabbatical period as Visiting Scientist at the Molecular Immunology Section (PI: Juan Rivera), National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, USA. He is an elected member of the Collegium Internationale Allergologicum (CIA).
Molecular mechanisms of cellular activation in chronic inflammatory diseases with a strong focus on mast cells.
Suresh Kalathil received his master’s degree (physiology /Biochemistry) from the University of Mumbai and Ph.D. in Immunology of cancer (Faculty of Medicine) from the University of Calicut. He worked as an Assistant Professor in the department of Biochemistry, Medical College, Kerala, India, where he was the principal investigator of the project entitled “Molecular detection of Human Herpes Virus-6 in oral carcinoma” funded by department of Science, Technology and Environment, India. He has published several papers in immunology and molecular biology of cancer in reputed journals, book chapters and received several awards and fellowships of national and international repute (National Board of Biotechnology, Indian council of Medical research). Later he moved to Canada and joined the group of Dr. Ronan Foley and Dr. Jack Gauldie at the Centre for Gene Therapeutics, Mc Master University, Canada, where he specialized in immunotherapy of human cancers. He had a leadership role in the development of dendritic cell based vaccine for the treatment of chronic lymphocytic leukemia patients. He joined the department of immunology, Roswell Park Cancer Institute in 2009 and since then he has been working on immune checkpoint receptors and immunesuppression in hepatocellular cancer patients and immune celldysfunction in chronic obstructive pulmonary disease (COPD).
Study on immune dysfunction and identification of biomarkers that predict treatment efficacy in patients with advanced stage hepatocellular carcinoma (HCC) who are currently being treated with the FDA approved drug called sorafenib and a second drug currently in clinical trials called tivozanib. Currently testing the hypothesis that patients with HCC receiving treatment with the tyrosine kinase inhibitors will exhibit a decrease in their immunosuppressive networks (Tregs, MDSC and exhausted PD-1 + T cells ) and thus increase the cytotoxic potential of the patient’s own effector immune T cells. Levels of T cell effector activity will be correlated with clinical endpoints (eg overall patient survival) to determine whether this could serve as a potential bio-marker for patients most likely to benefit from the drug treatment;
Understanding immune cell defects in patients suffering from chronic obstructive pulmonary disease (COPD). COPD is a leading cause of death worldwide and is initiated mainly by tobacco smoking. Our recently published studies provide for the first time clear evidence that functionally suppressive T regulatory cells and exhausted T cells are two major factors contributing to effector T-cell dysfunction in patients with COPD.Currently studying the importance of immune checkpoints and their inhibitors as potential targets for treatment of COPD patients.
Tong Shi, Ph. D. Pharm. D. has led research to understand the pathogenesis of a variety of immune-related diseases and to develop new therapeutics. He is currently working at Seaside Therapeutics engaging in the research effort on drug development and hematopoiesis. Prior to that, he was working on drug discovery targeting colorectal cancer. He accomplished his post doctoral training at Harvard Medical School, where he was one among the first researchers who proposed the functions of basophils in the maintenance of Th1/Th2 cell balance. He also visited Australia, which he discovered a novel mechanism of autoimmune-mediated thrombosis. He has published several pioneering studies in peer-reviewed journals.
The pathophysiology of immune-related diseases and cancer, functions of enzymes in the pathogenesis of immune-related diseases and cancer, novel therapeutics for immune-related diseases and cancer, such as small molecules and stem cells.
Isthak Golan qualified to PhD level in Cell Research and Immunology Department, Faculty of Life Sciences, Tel-Aviv University, Israel. He have 14 scientific publication in professional journals and 35 patents in the field of cancer and autoimmune diseases (rheumatoid arthritis). Most of professional research was focused in commercial projects. During 12 years from last 15 years, since he finished his PhD work, he was working in biotechnology companies and developed unique and specific technology / IPs related to the projects I led. This is why the majority of my publications are patents. His track record of raising £1.88 million in research funding demonstrates his ability to deliver on challenging deadlines and investment needs. During last 5 years he collaborating with 18 European Universities via participation in FP7 program for arthritis research at different levels within and outside the College of Medicine, Swansea University.
collaborations, in last 10 years including also more than 15 big, medium and small biotechnology / pharmaceutical companies from USA and Europe as well as governmental organizations (Israel, UK and European Commission). From 2012, He is serving in the European Commission in Brussels as expert / projects evaluator. In last 10 years he demonstrated and prove good appreciation of the commercial potential of research.
Late Phases of Malignant and Autoimmune-Inflammatory Processes
Dr Said Dermime received his Master and PhD degree in immunology from Salford University, Manchester, UK in 1987 and 1992 respectively. He joined the NCI, Milan, Italy for a period of 2 years as postdoctoral fellow and he then joined the NHLBI, NIH, Bethesda, USA, for a period of 2 years under an NIH Fogarty International Award. He was appointed after this period at the Paterson Institute for Cancer Research, Manchester, UK, as a lymphoma-cancer-vaccine Team Leader for 4 years. Subsequently, He established and led the Tumor Immunology Section at King Faisal Specialist Hospital & Research Centre, Riyadh, KSA, for a period of 6 years as a senior scientist. He joined the Dasman Diabetes Institute in Kuwait in 2008 to establish and lead the department of Biomedical Research and to head the Immunology & Innovative Cell Therapy Unit. In December 2012, He joined King Fahad Specialist Hospital in Dammam, Saudi Arabia to establish the Biomedical Research Facility and to head the Immunology & Innovative Cell therapy Program.
He is currently a member of several international scientific societies and he is also an active member of the editorial board of some Immunology Journals and member of scientific boards of some international organizations. He supervised several PhD and Master students and received several research grants from different organizations. He published over 42 peer-reviewed articles in high impact factor journal such as Blood, Cancer Research, Journal of Immunology, Clinical Cancer Research, Neoplasia, and Breast Cancer Research.
Innovative Cell Therapy: To discover novel tumour antigens as potential cellular immune targets to be used for cancer vaccine and/or adoptive cell therapy modalities; Immune Regulation; To investigate the effect of immuno-inhibitory molecules (such as B7-H1, PD-1) and/or regulatory T cells on the down-regulation of the immune response of patients with cancer and to develop immune-based therapeutic drugs to modulate the immune response in these patients; To design and carry out immune-based therapeutic clinical trials in cancer patients; Development and/or standardization of reliable and sensitive assays to monitor immune responses in cancer patients.
Dr. Ebenezer Satyaraj graduated with a Masters degree in Medical Microbiology from University of Madras, Madras, India in 1990. He completed his formal education by earning a Doctor of Philosophy degree in Immunology from the National Institute of Immunology, New Delhi, India in 1996. He continued his training at the University of Chicago, Illinois, as a Postdoctoral Fellow in Department of Molecular Genetics & Cell Biology doing research in Molecular Immunology. He subsequently accepted an Instructor’s position at the Department of Medicine, Northwestern University Medical School, Chicago, where he taught Immunology and conducted research in the area of autoimmunity. In 2001 he joined Molecular Staging Inc. New Haven, Connecticut, a biotech company started with technology from Yale University, working in the area of cytokines and disease biomarkers. At Molecular Staging Inc. He lead research collaborations with universities and the pharmaceutical industry, resulting in two seminal publications one on cytokine biomarkers for cerebral palsy & the other on biomarkers for inflammatory bowel diseases and numerous patents. He joined Nestle Purina in 2003 where he currently serves as Group Manager, Nutritional Immunology at the Nestle Research Center in St Louis, MO, leading a team that focuses on research in the area of nutritional immunology & cytokine biology. He has authored numerous scientific papers in the areas of cellular / molecular immunology and cytokine biology, including a recent publication in the journal Science that explains size variations in dogs and lectures internationally in the area of Nutritional Immunology. He is a member of the American Association of Immunologist and the American Veterinary Immunology Association, serves on the Editorial Board of ‘International Journal of Immunological Studies’ and is a reviewer for several journals including British Journal of Nutrition, Arthritis & Rheumatism and Journal of Gerontology.
Dr. Linglong Zou is currently the Director of Experimental Immunology in Teva Pharmaceuticals. He graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences with PhD in Pharmacology. He received postdoctoral training in Immunology, Neurology, Cell and Gene Therapy at Baylor College of Medicine. Linglong joined Teva in January 2012. In his current role, Linglong oversees immunogenicity assessment activities, including crafting immunogenicity assessment strategy, directing bioanalytical activities, interpreting immunogenicity data, and preparing regulatory filing and correspondence related to immunogenicity. Prior to Teva, he worked at two contract research organizations, including PRACS Institute as the Director of Ligand Binding Laboratory (2010-2011) and Bridge Laboratories as the Director of Immunology (2007-2010), where he directed bioanalytical method development, validation, and sample analysis activities for immunogenicity assessment, pharmacokinetic and pharmacodynamic analyses. From 2001 to 2007 he was Bioanalytical Scientist and Bioassay Group Leader at Tanox, Inc. (now Genentech Inc.) where he established a cell-based assay laboratory and developed assays to support potency and neutralizing antibody testing. He is an active member of American Association of Pharmaceutical Scientists. Over his industry career, he has contributed to approval of several biologics in US or EU markets.
Immunoassay and bioassay development and validation; immunogenicity risk assessment; characterization and interpretation of unwanted immune responses of therapeutic proteins, peptides, and other complex drug products; immunotherapy
Dr. Shahram Salek Ardakani received his M.Sc. in Immunology and Immunogenetics at University of Manchester, U.K, in 1997, and PhD at the Paterson Institute for Cancer Research (Manchester University) in oncology and viral immunology in 2001. He completed his postdoctoral training at the La Jolla Institute for Allergy and Immunology (LIAI), a private, non-profit research organization that specializes in research of the immune system. During that time he was the recipient of several institutional young investigator awards as well as awards from the National Institute of Health (NIH) for his work on how various members of the tumor-necrosis-factor receptor (TNFR) family control the response of CD4 and CD8 T cells at mucosal sites. He has worked on several interactions within this superfamily, focusing on those of OX40 with OX40L, 4-1BB with 4-1BBL, CD27 with CD70, and LIGHT with HVEM.He possesses a number of patents directed at immune disease therapy targeting the TNFR/TNF family. In 2012, he moved to the University of Florida College of Medicine as an Associate Professor were his research is directed towards a better understanding of virus-host interactions and the immune response to infection with a view to developing more effective vaccines and selective treatments against respiratory viruses. His group is pursuing this goal using models of lung inflammation and viral infection. He has served on a number of study sections for National Institute of Health and is considered an expert in the field of T cell biology and costimulation.
Defining the intercellular communication pathways that control the development of effector and memory T cells in the lung. His work has implications for understanding how to best elicit T cell responses to augment immunity against highly virulent respiratory viruses, but also for understanding how to down regulate responses to control excessive inflammation and pathology.
Dr. Ligia Pinto completed her PhD in 1995 at the Experimental Immunology Branch, National Institutes of Health, after several years of research on cellular immunology of HIV infection at the University of Lisbon, School of Medicine in Portugal. She continued her postdoctoral studies at NIH where she focused on investigating immunological alterations induced by HIV as well as host protective immune responses that may control HIV replication and associated immunopathogenesis. In 2001, she became the head of the HPV Immunology Laboratory at the Frederick National Laboratory for Cancer Research, where she leads a team of scientists, postdoctoral fellows, research associates and students doing research on immune responses in the context of HPV infection and cancer, as well as HPV vaccines. More recently, she expanded her research into other cancers with the goal of identifying markers predictive of cancer risk and prognosis.She has worked in the area of immunology of infectious diseases, vaccines and cancer for the last 27 years, with over 80 peer-reviewed publications, has many invited international presentations and received a number of distinguished scientific awards.
Antonio Simone Laganà was born in Reggio Calabria (Italy) on 8th May 1986. He is of Member of the Italian Association of Endometriosis, Society for Reproductive Investigation (SRI), European Society of Human Reproduction and Embryology (ESHRE), International Society of Gynecological Endocrinology (ISGE), Society of Endometriosis and Uterine Disorders (SEUD), International Society of Ultrasound in Obstetrics and Gynecology (ISUOG). He got a Master of “gynecological minimally invasive and robotic surgery” (University of Pisa), developed an intensive surgical training in the Univerzitetni Klini?ni Center, Ljubljana (Ljubljana, Slovenia) and obstetric/gynecological ultrasound training in the Altamedica Main Center (Rome, Italy). His research interests are: Endometriosis, Reproductive Immunology, T cell subsets, Chronic Pelvic Pain, Genetic of Mullerian-Derived Structures, Gynecological Endocrinology, Polycystic Ovarian Syndrome, Laparoscopy and Hysteroscopy. He is author of many papers published in national and international peer-reviewed journals, and his presence is often requested as Invited Speaker in international congresses.
Florence Lambolez received her M.Sc. in Biochemistry from the University of Dijon, France, in 1996. She then moved to the Necker Institute-University Rene Descartes where she obtained her PhD in Immunology in 2003 under the supervision of Dr. Benedita Rocha. During this period, she made significant contribution to the characterization of the extrathymic differentiation pathway of unconventional mucosal DN T cells. In 2004 for her postdoctoral training, she joinedthe laboratory of Dr. Hilde Cherou treat the La Jolla Institute for Allergy and Immunology (LIAI), a private, non-profit research organization that specializes in research of the immune system. During that time she was the recipient of HFSP long-term fellowship award and studied the thymic agonist selection pathway of DN TCRαβmucosal T cells. In 2008, she was promoted as Instructor at LIAI and started a new line of research aiming to define the MHC specificities of DN mucosal T cells and the antigen recognition at the mucosal border. During this period, she was awarded two grants from the National Institute of Health (NIH) for her work and made the ground breaking discovery that DN TCRαβ intraepithelial T cells are not restricted to a particular major histocompatibility complex (MHC) class I or class II molecule, but instead their MHC restriction is variable ranging from classical class I to non-classical MHC class I complexes. She is considered an expert in the field of mucosal unconventional DN T cell development and biology.
Thymic T cell development; Agonist selection process; MHC restriction; MHC-peptide/TCR recognition; mucosal DN T cell biology
Selliah earned his doctorate degree in Immunology from the University of Kentucky, Lexington, KY, USA. He did his Postdoctoral research training at the National Jewish Medical Center, Denver, CO, USA, on HIV and T-cell biology. He investigated the biochemical and signaling effect of HIV-induced T-cell energy and apoptosis. His research continued to The Children’s Hospital of Philadelphia (CHOP), Philadelphia, PA, as his mentor moved to CHOP. He continued to study HIV and T-cell biology, including TCR/CD3 signaling, cytokine signaling (JAK3/STAT5) and HIV latency. His research findings lead to several peer reviewed publications. His interest in HIV and translational research lead him to Roger Williams Medical Center to pursue a new technology in immune therapy, known as CART or Chimeric Antigen Receptor Therapy. His work on CART for HIV has been published in Virology (2013). His passion in translational research moved him to a biotech company, HUMIGEN LLC, in NJ, USA. He became a Team Leader to develop a project on biomarker discovery for lupus disease. He utilized Flow cytometry and qPCR technologies to identify biomarkers in blood from lupus patients. While he was at the HUMIGEN, LLC, got an opportunity to join Rowan University as an Adjunct Assistant Professor and to teach immunology and a seminar course to Master’s degree students. He was a consultant/scientist with Celgene Cellular Therapeutics. He continue to have a passion in research and teaching. He is also in the Editorial board (Associate Editor) of another journal, American Journal of Clinical and Experimental Immunology.
HIV-induced T-cell energy; Apoptosis; HIV latency models; Understanding the induction of latency; Reactivation from latency; HIV immunotherapy; CART for HIV; Biomarker discovery for autoimmune diseases; Lupus; RA; IBD; Cancer immunotherapy; CART; Immune-modulation (T-cell signaling and regulatory T-cells); PI3K/Akt/mTOR signaling pathway in T-cells
Sakhrat Khizroev is a Professor at the FIU College of Medicine (with tenure at the College of Engineering) with a research focus on the basic study and development of groundbreaking applications in cancer, immunology, neuroscience, cardio-vascular medicine, and ophthalmology.
In 2011, he came back to FIU to undertake a challenging task of working hand-in-hand with his colleagues at the recently established Herbert Wertheim College of Medicine to create a world-class university-wide center in the emerging field of patient- and disease-specific medicine (Personalized Nanomedicine). The main mission of the Center is to use nanotechnology to bridge advances in fundamental research with the current need in medicine. The focus is on research to impact everyday clinical applications. He started his medical career as a Professor at the Department of Immunology where he also served as Vice Chairman. Since 2014, his main appointment is at the Department of Cellular Biology and Pharmacology – the heart of research at the College of Medicine. From 2006 to 2011, he was a tenured faculty (Professor in 2009-2011 and Associate Professor in 2006-2008) at the Department of Electrical Engineering of the University of California, Riverside (UCR). He started his academic career in 2003 as an Associate Professor at the Department of Electrical and Computer Engineering at FIU, where he was tenured in 2005.
Prior to his academic career, he spent four years as a Research Staff Member with Seagate Research (1999-2003) and one year as a Doctoral Intern with IBM Almaden Research Center (1997-1998). He holds over 30 granted patents and 130 provisional patents with IBM, Seagate, CMU, FIU, and UCR. He has authored/co-authored over 120 refereed papers, 5 books and book chapters in a broad range of nanotechnology applications with an emphasis on the physics of nanomagnetics/spintronics. He has presented over 100 talks including many invited seminars and colloquia at international conferences and meetings. He has acted as a guest science and technology commentator on television and radio programs across the globe. He was one of the co-founding editors for IEEE Transactions on Nanotechnology, a guest editor for Nanotechnology and IEEE Transactions on Magnetics. He sits on editorial boards of several Science and Technology journals. He received a BS in Physics from Moscow Institute of Physics and Technology, a MS in Physics from the University of Miami, and a PhD in Electrical and Computer Engineering from Carnegie Mellon University in 1992, 1994, and 1999, respectively.
Nanoscale devices and systems to enable patient- and disease specific medicine (Personalized NanoMedicine) with a focus on applications in cancer, immunology, neurological diseases and neuroscience and neuro-imaging, ophthalmology, and cardio-vascular diseases
Mehrdad Ameri, Diplomate ACVP is a clinical pathologist/immunologist with over 19 years of experience in both academia and pharmaceutical industry. Before joining the pharmaceutical industry, he was an assistant professor of immunology and clinical pathology at Iowa State University. He is currently an adjunct professor of clinical pathology at the Department of Diagnostic Medicine and Pathobiology, Kansas State University. His career in the pharmaceutical industry began at Wyeth and then Pfizer where he worked as a senior pathologist on regulatory GLP and non-GLP toxicology studies on candidate drugs and medicine for human. He joined Amgen in 2011 as the Director of Clinical Pathology and Translational Safety Biomarkers Laboratories. Currently, he is a senior pathologist at Charles River Laboratories. He served in the American College of Veterinary Pathologists Board ExaminationsCommitteein 2013 and 2015. In 2013 he was invited by CDC to serve in a special panel to assess past and present performance of the malaria research and to provide recommendations for future research initiatives and projects. He is an author / co-author of more than 100 scientific publications. He is a section editor for Veterinary Clinical Pathology and a member of several national and international scientific organizations including American College of Veterinary Pathologists (ACVP), American Society for Veterinary Clinical Pathology (ASVCP), Society of Toxicologic Pathology (STP), American Association for Clinical Chemistry (AACC).
Immunoassay; Biomarkers; Immunotoxicology; Immunotherapy of Hematopoietic Neoplasms; Infectious Diseases; Autoimmunity and Inflammation
Blaise Bikandou is a Senior Global Health Professional with over twenty years of international experience in clinical medicine, immunology and molecular biology, health program developments, public health and human development and health sector governance. Prior to his commitment in global health and human development, he was involved in clinical and biological aspects encompassing in haematology and immunology, infectious diseases at Assistance Publique Hôpitaux de Paris for more than a decade. With in-country residence and field operations in developed (France, Japan, US) and developing countries (more than 20 developing countries), he has conducted various researches on HIV/AIDS that include epidemiology, cellular and molecular biology, clinical trial and vaccines research approaches and delivery. Awarded for various research grants from NIAID/NIH in US, Mombosho (Japanese ministry of education and research), ANRS from France, and other states or privates research funding agencies, as principal investigator, he has coordinated and implemented various projects and programs in public health diseases.
He is former director of the department of preventive medicine, epidemiology of transmissible diseases and clinical trial at the National Institute of Public Health (Pasteur Institute of Brazzaville). He has demonstrated track record of delivering training, education, support and assistance in public health issues. He has published over twenty articles and has been involved in public health several seminars. He is also a member of several technical review committees (Global Fund against HIV/AIDS, Malaria and TB -Global Alliance for Vaccines and Immunization), various medical and scientific professional organizations and human development associations. He is also engaged into various initiatives such as think-tank on global health, governance and education “global population health and well-being in the 21st Century: towards a new worldview.
He is an outstanding leader, mentor and strategist (fluent in English and French) with a vast network of high level partners across both government and non-government organizations, United Nations Agencies, private sectors actors as well as partners of development committed in science of life, public health and human development. He is displaying detail-oriented and strong aptitude for handling professional challenges while ensuring quality service delivery.
He holds an Executive Health MBA from the High School of Public Health-ESCP-Europe- Columbia University (US), PhD from Rene Descartes University (Paris), Master degree and a Medical Biology degree from Rene Descartes University (Paris), Diploma of transmissible diseases from the University Medical School of Massachusetts (US), Diploma of immunology from Pasteur Institute (Paris) and M.D. from Marien N’Gouabi University.
Epidemiology of Transmissible Diseases; Molecular Epidemiology of HIV/AIDS
Jun-Jie Chen is an Assistant Investigator at the Tumor research laboratory, department of medical research, E-da hospital in Kaohsiung, Taiwan. He also served adjunct professor in I-Shou University, school of medicine. He has over 10 year’s research experience in the cancer research. He also leads a research team in the conduct of mission related research program, including the discovery of biomarkers for evaluation of oncology drug products by using pharmacogenomics. His scientific expertise lies in the areas of signal transduction, cell death regulation, cancer therapeutics, drug resistance mechanisms, and cancer biomarkers as evidenced by peer-reviewed articles. Prior to joining E-da hospital, he was a research fellow at division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA). He earned his Ph.D. in pharmacology from National Taiwan University in 2007. He has received many awards in scientific society including the outstanding award of Wang Ming-Ning foundation in 2006.
Signal transduction; Cell death regulation; Cancer therapeutics; Drug resistance mechanisms; Cancer biomarkers
Dr. Theocharis G Konstantinidis MD, PhD candidate in Immunology at the Laboratory of Molecular Haematology of Democritus University of Thrace. He graduated from the Kuban State Medical Academy of Krasnodar, Russia in 1998. He completed his training in Medical Biopathology (Laboratory Medicine) at the University Hospital of Alexandroupolis in 2008. He received training in immunology at the Medical Research Center “Immunculus” in Moscow. He also completed his Master from Medical School of Democritus University of Thrace in 2012. Since 2008, he is Technical Manager of Regional Public Health Laboratory of Hellenic Centre for Diseases Control and Prevention. He has contributed and co-authored publications in peer review papers.
Dr. Champa N Codipilly is a Research assistant investigator at the Department of Pediatrics/neonatal Research at the North Shore Long Island Jewish Health System (NSLIJHS) and the Feinstein Institute of Medical Research at the NHLIJHS. Additionally she serves as a board member of the NSLIJHS’s Institutional Review Board. She received her PhD from the State University of New York at Stony Brook. She completed her post-doctoral research fellowship at Department of OB/GYN at the University Hospital at Stony Brook. Her thesis work involved exploring biochemical characteristics of vaginal microbial ecology and its implications on bacterial vaginosis.
Microbiology, immunology and inflammation. Infantile nutrition and its influence on establishment of gut microbiome and disease development specially related to Necrotizing enterocolitis are her main area of research. Her current work involves investigating nutritional, pro-biotic and pro-absorptive values of human milk, formula and dietary supplements on infant gut health and disease.
Deshanie Rai, currently Senior Associate Director at Bayer Healthcare, is an accomplished scientist within the corporate and academic sectors. Her professional career began in South Africa where she practiced Clinical Nutrition. After completing post-doctoral training, she joined Global Research and Development, Mead Johnson Nutrition with roles in Discovery, Global Infants and Scientific Affairs functions. At DSM, She supported the Innovation team to translate and commercialize the science on its product portfolio. In her current role, Deshanie provides scientific and technical leadership to implement strategic objectives related to new business and product opportunities. Her research has focused on the role of nutrients, bio actives, enzymes, and pro- and prebiotics on gastrointestinal health, including mucosal immunology. She has co-authored several peer-reviewed publications and patents. She has been an invited speaker at national and international meetings, including webinars and media interviews. She has been the recipient of several awards including the Young Investigator Award, a two-time recipient of the Mead Johnson President’s Award, the Tribute to Women and Industry Award and most recently, the Bayer Healthcare Leadership Applause Award. She also serves as an Adjunct Associate Professor at Tufts University and the University of Illinois, where she is involved in guest lecturing, mentoring students, and supporting their research efforts. Currently, Deshanie leads the Power Me Program under the Women’s Leadership Initiative at Bayer Healthcare; is Co-Chair for the Women in Science Affinity, HBA Metro; and is on the Leadership team for the Vitamin and Mineral Research Interest Section within the American Society of Nutrition.
Annu Khajuria is a dedicated, highly regarded and motivated Technical Consultant, with a wealth of transferable skills and a strong academic background. Possesses 12 years experience as a Clinical Biochemist, with more than 20 years total research experience. A resourceful and dedicated leader who thrives in challenging working environments, while maintaining the highest of clinical standards. A hard working, driven and highly committed individual, with a passion for empowering students through providing encouragement, support and exemplary instruction. Possesses excellent interpersonal and communication skills and the ability to develop and maintain positive internal and external relationships at all levels. A loyal, approachable and trustworthy team player with natural leadership skills and a wide knowledge of diverse cultures, races and religions, who inspires respect from colleagues and superiors alike. Her skills and expertise include but not limited to; Laboratory Management and Operations, Strategic Operations/ Planning, Budgeting, Team Management, Training & Mentoring, Method evaluation Validation & Development, Quality Design and Planning, Six Sigma analytics, Laboratory Automation
She has Hon B.Sc. and M.Sc. degrees in Biochemistry from the University of Nagpur, India. She obtained her Ph.D. degree from the University of Jammu, India and pursued postdoctoral fellowship from Manitoba Institute of Cell Biology, Winnipeg, Manitoba, Canada. In 2004 she completed Post-doctoral Training Program in Clinical Chemistry at the University of Manitoba, Winnipeg. She is certified as a Clinical Biochemist, fellow Canadian Academy of Clinical Biochemists and fellow Academy of Clinical Biochemistry and Green belt in Six Sigma. Worked as Clinical chemist at Department of Clinical Chemistry, Winnipeg Manitoba till 2005 and then moved as AssociateDirector to University of Texas Medical Branch, Critical Managed Care and Outreach Laboratory Services, Health Services Administration at Huntsville and Assistant Professor in Department of Pathology at University of Texas Medical Branch at Galveston, Texas, USA. In 2007 decided to come back to Canada and till 2010 was Clinical Biochemist at DynaLIFEDx and, Assistant Clinical Professor, Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, Canada.
She was Section Head, Core Chemistry & Medical Director Regional Centers in Department of Laboratory Medicine & Pathology, Marshfield Center, Marshfield Clinic, Marshfield, WI, USA from 2011 to 2014. Served as technical consultant for Core Chemistry, Core Chemistry Regional centers, Immunochemistry, Special Chemistry, Urinalysis & POCT for Marshfield Clinic.
Currently she is working as Technical Director for Central Lab for Covance-LabCorp Clinical Trials.As Technical Director of Central Laboratories her role is to provide overall direction for laboratory operations and scientific functions within the company to service clients and patients (clinical trial subjects) in accordance with industry standards of scientific integrity and regulatory requirements.A multi-faceted role, providing technical direction in areas of core lab, general and special chemistry, immunology, endocrinology, infectious disease testing, Urinalysis, routine hematology, coagulation, molecular diagnostics including interpreting and signing out clinical laboratory tests.
She has also been active within Canadian Society of Clinical Chemists and served as Councilor, Canadian Society of Clinical Chemists Executive Committee, Treasurer, Alberta Society of Clinical Chemists, and Member - CSCC Panel for Electronic Health Record. Currently she is Board of Director, Chair Accreditation Committee, Syllabus Revision Committee Canadian Academy of Clinical Biochemistry since July 2009 and member CSCC Working Group on Quality Management. She has won CSCC International Travel Grant and CSCC Leadership/Administration Grant. She has several peer-reviewed publication and abstracts to her credit.
Quality system design and Six Sigma; Automation and workflow analytics in core laboratory; Data mining and trends evaluation
Jayshree Mishra received her PhD in 2005 from the Indian Institute of Technology Kharagpur in India. She completed her postdoctoral training at the University of Tennessee, College of Medicine and College of Pharmacy. Currently she is a Research Assistant Professor in the Department of Pharmaceutical Sciences at the Irma Lerma Rangel College of Pharmacy (Texas A&M University). She has published several papers in the reputed journals in peer review journals, book chapters, and also the recipient of several awards and honors of national and international repute. She has been active in various national and international societies and served as an organizing committee member in Nutraceuticals-2015, Pharmacovigilance-2014, Pharmacovigilance-2013. She has a long time experience working in mucosal inflammation; especially finding therapeutic targets to regulate mucosal inflammation. She has been awarded with several Fellowship of national and international in nature such as DAAD Fellowship; Government of Federal Republic of Germany (2003- 2004), Jawaharlal Nehru Memorial Fund Award; India, Delhi (2001-2002), ACCP-TAP Pharmaceuticals GI Investigator Development Research Award from ACCP Research Institute (2006). Currently she is the Co-Principal Investigator of NIH-SBIR funded project.
Chronic mucosal inflammation is the leading cause of several diseases such as Ulcerative Colitis; Crohn’s Disease; Epithelial Cancer and particularly; IBD induced colorectal cancer; Finding the therapeutic targets to regulate mucosal inflammation without compromising the healthy immune functions
Kulvinder S Saini is currently working as a Senior Consultant & Professor of Biotechnology and Genomics at King Abdulaziz University (www.kau.edu.sa), Jeddah, Saudi Arabia. Earlier (2010-2012), he was Director-R & D and Dean-Academic Affairs at Eternal University (www.eternaluniversity.edu.in) Baru Sahib, Himachal Pradesh, India. His previous assignment (2002-2010) was as a Director of Biotechnology and Bioinformatics at Ranbaxy (www.ranbaxy.com) (number one pharmaceutical company in India with annual revenues of US$ 2.25 billion in 2012).
His international work experience includes 9 years in U.S.A (including 3.5 years as Research Fellow at Harvard Medical School, Boston), 7 years in Australia (including Senior Research Fellow at the Princess Alexandra Hospital, Brisbane and Senior Scientist at CSIRO, Sydney) and 10 years in India (including 8.3 years as Director-Biotechnology & Bioinformatics at Ranbaxy). He obtained his Ph.D. in Animal Biochemistry from Sydney University, Australia and did a postdoctoral fellowship in Molecular Endocrinology at the Department of Biochemistry, Case Western Reserve University Medical School, Cleveland, Ohio, USA. He is an active member of the American Society for Biochemistry and Molecular Biology (since 1988) and American Association for Cancer Research (since 1989).
He has attended numerous business & scientific meetings (Due diligence, M&A, Conferences, etc.) in Australia, Europe, South-East Asia, China, UAE, UK and USA. He is the author/co-author of 138 monographs: 123PUBLICATIONS (including 52 conference posters/presentations,) 2 BUSINESS/I.P. ARTICLES, 1 invited BOOK REVIEW and 2 dissertations) and 15 PATENTS (8 granted/published). In addition, He has delivered 38 INVITED LECTURES at national & international conferences in Australia, China, India, Saudi Arabia, Singapore, South Korea, United Arab Emirates & United Kingdom.
Cancer Stem Cells, New Drug Discovery, Pharmaceutical Biotechnology, Genomics, Protein Expression Optimization, Diabetes, Obesity, Plant Alkaloids, Complementary and Alternative Medicine
Xiaofa Qin obtained his MD, PhD in Beijing Medial University, Beijing, China then became a lecturer and associate professor there. Later, he came to the United States and engaged in medical research as a postdoc, research instructor and assistant professor consecutively in Louisiana State University (LSU) Medical Center in Shreveport, University of Cincinnati college of Medicine, and University of Medicine and Dentistry of New Jersey (UMDNJ, now merged with Rutgers)-New Jersey Medical School. He found that digestive proteases such as trypsin and chymotrypsin can be inactivated by unconjugated bilirubin but not conjugated bilirubin. He proposed that an impaired inactivation of digestive proteases as the result of reduction in gut bacteria, thus the enzyme needed for deconjugation of the mainly conjugated biliary bilirubin, along with improved hygiene and inhibition by dietary chemicals such as the widely used artificial sweeteners saccharin and sucralose may have played important causative role in inflammatory bowel disease (IBD, including ulcerative colitis and Crohn’s disease) and other diseases of autoimmune, allergic, etc, through damage of the mucus layer and underlying gut tissueby the poorly deactivated digestive proteases and increased infiltration of bacterial and dietary components from gut lumen. Recently, he founded GI Biopharma Inc to develop some new treatments for IBD and other diseases.
The role of changes in microbiota of the gut and impaired inactivation of digestive proteases in pathogenesis of the many remarkably increased autoimmune; Allergic and other diseases in modern society
Firdos Alam Khan, Full Professor, and Chairperson, Department of Biotechnology, Manipal University, Dubai, (www.manipaldubai.com) UAE received his Doctoral degree in Neuroscience from Nagpur University, India. He has 20 years of research and teaching experience in various domains of biotechnology. He did his first postdoctoral research from National Institute of Biological Science, Tata Institute of Fundamental Research, Bangalore, India (www.ncbs.res.in) and second postdoctoral fellowship from Massachusetts Institute of Technology, Cambridge, USA (www.mit.edu). He was associated with Long Beach Medical Center, California, USA as an Associate Research Director for a neurological disorder project. He worked with Reliance Life Sciences a multimillion dollar Biotech Company based in Mumbai, India, (www.rellife.com) as a research scientist and worked on adult and embryonic stem cell projects. His area of specialty in biotechnology includes stem cell technology, neuro pharmacology, and neuroscience. He has written numerous articles in various national and international journals in the areas of neuroscience, neuro pharmacology and stem cell biology. He has been awarded two US patents on his discovery in the stem cells. Recently he has been nominated as an International Advisor Board member for World Biotechnology Congress, UAE where four distinguished Noble Laureates are also members (http://www.biotechworldcongress.com/advisoryboard.php) He has also been nominated for member of scientific advisory committee for Pharmaceutical & Biotechnology Middle East, (www.pabme.com). He has been associated with various international scientific organizations like International Brain Research Organization, France, and Society for Neuroscience, USA. He has worked experience in multi-cultural environment with different positions such as researcher, teacher, academic administrator and educationist. He is known for his role in promoting biotechnology education in the Middle East. He has presented at more than 20 different national and international conferences in India, China, Singapore, UAE, Thailand, and USA.
Alessandra received her undergraduate degree in Biological Sciences from the University of Milan, Italy, in 1998. She then moved to San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET) where in 2005 she obtained her PhD in Cellular and Molecular Biology co-sponsored by the Open University of London (UK) and the Vita-Salute University San Raffaele (Milan, Italy) under the supervision of Prof. Maria Grazia Roncarolo and Dr. Alessandro Aiuti. During this period, she significantly contributed to the development of gene therapy trials for ADA-SCID by infusions of engineered retrovirally transduced PBL or CD34+ cells combined with a non-myeloablative conditioning with busulfan. She also studied the efficacy and safety of gene therapy mediated by lentiviral vectors in the ADA-deficient animal model. At the beginning of 2006, she joined the laboratory of Prof. Paola Castagnoli at the Department of Biotechnology and Biosciences, University of Milano-Bicocca, where she studied the molecular mechanisms triggered by the inflammatory process induced by pathogens (i.e. M. tuberculosis) and danger signals alerting the immune system. In 2008, she had the opportunity to move to Singapore as Research Scientist under Prof. Castagnoli and continue her studies in a new and vibrant international research institute. As of 2011, she has been a Principal Investigator at SIgN, with responsibility for a group of 5 scientists.
Innate molecular mechanisms driving inflammation in mice and humans, Implications of the inflammasome in immune regulation and disease pathogenesis
As a graduate student, Margaret A Bakerbecame interested in the impact of oxidative stress on cells and was able to elucidate the generation of peroxide during the metabolism of toxins from fava beans by red blood cells thereby explaining a possible mechanism of hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase deficiency. She subsequently worked on the role of selenium-dependent glutathione peroxidase activity in rheumatoid arthritis and inhibition by gold salts. As a post-doctorial at Stanford University, my team worked on radiation-mimetic drugs and showed that the compound now known as tirapazamine is able to act as a single electron acceptor and cause ionizing radiation-like damage to cells, particularly the DNA. As an academic researcher and project director until 1996, I supervised a number of efforts to understand thiol-dependent cellular damage and repair and pharmaceutical drug discovery on various methods of action that lead to cellular damage and possible cancer therapeutics.
After leaving laboratory research and spending several years in competitive intelligence and market research, she became a patent agent (2000). She supported teams in small and large molecule drug discovery by capturing, creating and managing intellectual property. She worked for Johnson & Johnson's antibody discovery company, Centocor, for 11 years, at which time it was absorbed into Janssen R&D. As a patent manage, she developed patent strategies for novel biopharmaceuticals, mostly monoclonal antibodies. She reviewed patent rights for 30+ biopharmaceutical licensing opportunities, drafted over 80 complex biotechnology and biopharmaceutical patents and assisted in prosecution and defense of patents.
As a freelance consultant, she continues to seek to help entrepreneurs, support innovative technologies and educate and assist inventors in protecting their intellectual property.
Yue Liustarted her scientific career as a graduate student at Soochow University, Medical College from 1994 to 1997. Her research project was to engineer mouse monoclonal antibody against human thrombi for thrombi imaging and thrombolysis. After graduating with Master’s degree in 1997, She went to Universitede Sherbrooke, Canada to have Ph.D. training in cancer biology and virology. From then to 2007, for both her Ph.D. training in Sherbrooke University and postdoctoral training at UCLA, She focused research on studying how adenoviral onco proteins inactivate critical tumor suppressors and the mechanism of action of oncolytic adenovirus. In 2007, she joined a start-up company in San Francisco bay area and came back to the antibody field again. In the past 8 years, she have taken advantage of experience and expertise to pioneer the development of new therapeutic antibodies and engineer these antibodies for better affinity and function. As a result of these efforts, her colleagues and she are working diligently to bring novel therapies to the clinic with the hope of ultimately improving overall survival for patients with tumors, neurodegenerative diseases and other diseases.
Antibody Discovery and Optimization; antibody mechanism of action study; oncolytic adenovirus mechanism of action study
Eva M Martínez-Cáceres obtained her PhD on the role of CD27 in human thymus at the University of Barcelona (UB) and trained as specialist in clinical Immunology at the Clinic Hospital Barcelona. Her post-doctoral research at H. Spits’ lab, at The Netherlands Cancer Institute (Amsterdam) was devoted to the mechanisms of human T-cell development. In 1996 she moved back to Barcelona, at the Clinical Neuroimmunology Unit, Vall d’ Hebron Hospital, where she started her research on the pathogenesis of multiple sclerosis (MS). In 2001 she moved to Germans Trias i Pujol Hospital, as consultant immunologist, where she expanded her scientific interest to other autoimmune diseases, tolerance and diagnostic immunology. Her research focuses on the analysis of peripheral tolerance mechanisms and their failure in organ-specific autoimmune diseases. By using in vitro and animal models, she aims at identifying new biomarkers for disease monitoring and prediction of treatment response. Since 2008 her main interest is the development of cell-based tolerance-inducing therapies for autoimmune diseases, specifically MS. Her group has developed a tolerogenic cellular product consisting of autologous monocyte-derived tolerogenic dendritic cells loaded with a pool of myelin peptides to treat MS patients. This therapy has been tested in animal models of MS and in being developed at a clinical scale in Good Manufacturing Practice conditions, in order to initiate a Phase I /IIa clinical trial in the near future.
Currently, she is Head of the Immunology Division and Associate Professor of Immunology at Germans Trias i Pujol Hospital, Autonomous University Barcelona (UAB) and member of the board of the Autoimmunity Group of the Spanish Society of Immunology. She is the Chair of the European COST Action A-FACTT (www.afactt.eu), which aims to focus and accelerate the development of tolerogenic cell therapies for autoimmunity and transplantation.
Analysis of peripheral tolerance mechanisms and their failure in organ-specific autoimmune diseases
Shokrollah Elahi obtained multiple academic degrees from the Tehran University of Medical Sciences, Iran, before moving to Australia in 1997. He received PhD from the University of Newcastle in 2002, where he studied host pathogen interactions in a mucosal model of candidiasis. He completed his first post-doctoral fellowship at the Vaccine and Infectious Disease Organization and International Vaccine Center, University of Saskatchewan. During his post-doctoral fellowship he developed a novel model of porcine pertussis and investigated the role of host defense peptides and maternal immunity in this model. He decided to expand his scientific vision by joining Seattle Biomedical Science Institute affiliated with the University of Washington where he studied HIV pathogenesis. Finally, he moved to Cincinnati Children Hospital Medical Center and investigated the Immune pathogenesis of neonatal infections before joining the University of Alberta in 2014.
HIV Pathogenesis; Immuno regulation; Innate and adaptive immunity; Neonatal immune system development; Red blood cells precursors (CD71); Biology and function in newborns
Robert C Shepard has been doing cancer research since his freshman year in college. He was graduated Magna cum Laude in Biochemical Sciences and Molecular Biophysics from Harvard College and spent my last year in the Harvard-M.I.T. Health Sciences Program. He earned his MD degree in the M.D.-Ph.D. Medical Scientist Training Program at Duke University which included two years in graduate school in immunology. His specialty (fellowship) training in both hematology and oncology was at Tufts-New England Medical Center where he did laboratory research in leukemias, myeloma, and myelodysplasia, and at the Dana-Farber Cancer Center and Harvard Medical School where he did a postdoctoral fellowship in Pharmacology and Molecular Genetics. His medical internship was at Memorial Sloan Kettering Cancer Center. He triple board-certified in oncology, hematology, and internal medicine; and have extensive experience in translational and clinical research in community as well as academic hematology/oncology with full-time academic appointments at Harvard, Tufts, and the University of Virginia. While at UVa, he served as Associate Professor, Director of Gastrointestinal and Genitourinary Oncology Phase I trials, and Developmental Therapeutics; and was the PI for ECOG. He also spent 6 months during that time in CBER at the FDA and was involved in the medical review of Avastin and Erbitux as well as other NMEs. He have extensively published in the peer-reviewed literature. He was study chair for numerous ECOG clinical trials in myeloma as well as breast and GI cancers; and on the Breast, GI, and Hematology Core Committees. He was also Co-Chair with Dr. Bob Kyle of the ECOG Myeloma Committee from 1985 to 2002. Since 2005, he have also been responsible for the complete clinical development of several drugs and immune therapies for several biotech companies, including functioning as the consulting CMO and representing them in pre-IND and EOP2 meetings with the FDA. He recently helped run a global registration trial for Infinity Pharmaceuticals, and He is the first External Reviewer for the Millennium Clinical Review Board.
Clinical trials which includes writing, implementing, accelerating enrollment, and successfully finishing trials in all phases. He have run SAB’s, MAB’s, as well as bid defenses, and completed RFP’s as well as the medical sections of numerous proposals.
Dr. Moustapha Hassan completed his M.Sc. in Toxicology-Chemistry at Alexandra University, Egypt, and received his Doctoral Degree from Uppsala University, Sweden, in 1987. He was made Associate Professor of Experimental Oncology at Karolinska Institutet in 1994, and became Professor of Experimental Hematology and Experimental Cancer Medicine in 2005. He is currently Director of the Preclinical Laboratory at Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden as well as Professor of Transplantation Research at Karolinska Institutet Huddinge, Stockholm, Sweden.
Personalized medicine; nanomedicine; pre-transplant medicine and he is the inventor of liposomal busulfan
Dr. Shara BA Cohen has been active in the scientific community for over 30 years. She started as a member of the British Association of Young Scientists at the age of 15, obtained her first science degree at 21 and her Immunology PhD at 25. She has been a research scientist and lecturer in prestigious institutions around the world [including Addenbrookes' Hospital (Cambridge), The Kennedy Institute of Rheumatology (London), The Mount Sinai Hospital (New York) and The Royal Postgraduate Medical School (London)]. She left mainstream science in 2001 research to follow her passion of science communication.
Pankaj Kumar is a Research Associate at Vaccine and Infectious Disease Organization-International vaccine center, University of Saskatchewan, Saskatoon, Canada. He has been working towards development of novel vaccines and immunodiagnostics tools, employing viral and non viral vector systems, for more than 10 years. He has expertise in immunology, molecular biology, cell biology and viral vector technologies. His current research involves design & development of novel live adenoviral vectored based platform technologies for efficient vaccine delivery.
To generate effective vectored vaccine platform technologies for the development of viral vaccines for emerging animal and human diseases.
Dennis Daniel Taub
Washington DC Veterans Administration Medical Center